UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 20-F/A

 

 REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934

 

OR

 

 ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended December 312025

 

OR

 

 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

OR

 

 SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Commission File No.: 001-38041

 

SCISPARC LTD.

(Exact name of registrant as specified in its charter)

 

Translation of registrant’s name into English: Not applicable

 

State of Israel 

(Jurisdiction of incorporation or organization)

 

20 Raul Wallenberg St.

Tower A, 2nd Floor

Tel Aviv 6971916Israel 

(Address of principal executive offices)

 

Oz Adler

Chief Executive Officer

Tel: +972-3-7175777

Email: oz@scisparc.com

20 Raul Wallenberg St.

Tower A, 2nd Floor

Tel Aviv 6971916Israel

(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)

 

Securities to be registered or to be registered pursuant to Section 12(b) of the Act: None

 

Securities registered or to be registered pursuant to Section 12(g) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Ordinary Shares, no par value    SPRC   The Nasdaq Capital Market

 

Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None

 

Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report.

 

365,444 Ordinary Shares, no par value, as of December 31, 2025 

 

 

 

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

 

Yes ☐  No ☒

 

If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act of 1934.

 

Yes ☐  No ☒

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

 

Yes ☒  No ☐

 

Indicate by check mark whether the registrant has submitted every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

 

Yes ☒  No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer Accelerated filer
Non-accelerated filer  Emerging growth company

 

If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

† The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. 

 

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. 

 

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

 

Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing.

 

U.S. GAAP ☐

 

International Financial Reporting Standards as issued by the International Accounting Standards Board ☒

 

Other ☐

 

If “Other” has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow.

 

☐ Item 17 ☐ Item 18

 

If this is an annual report, indicate by check mark whether the registrant is a shell company.

 

Yes ☐ No 

 

 

 

 

 

 

EXPLANATORY NOTE

 

Due to an administrative error, we are filing this Amendment No. 1 (“Amendment No. 1”) to our Annual Report on Form 20-F (the “Original Filing”) for the sole purpose of amending Item 18 of the Original Filing to: (i) include the Report (the “Report”) of our Independent Registered Public Accounting Firm by Kost Forer Gabbay & Kasierer, a Member of EY Global (“EY”) dated as April 24, 2025 (except for Note 1(d), as to which the date is July 8, 2025); and (ii) add Note 1(d) to the audited consolidated financial statements. The Report of EY that was included in the Original Filing was not the most recent auditor’s report on the financial statements as of December 31, 2024, and for the two years ended on that date. The most recent auditor’s report included dual dating as a result of a one-for-twenty one reverse share split of the Company’s issued and outstanding ordinary shares, no par value per share, effected on July 3, 2025. For clarity, the audited consolidated financial statements as of and for the two fiscal years ended December 31, 2025 included in this Amendment No. 1 are otherwise unchanged, with the exception of the inclusion of Note 1(d), from the audited consolidated financial statements included in the Original Filing.

 

In addition, pursuant to Rule 12b-15 under the Securities Exchange Act of 1934, as amended, the certifications pursuant to Section 302 and Section 906 of the Sarbanes-Oxley Act of 2002 have been re-executed as of the date of, and are re-filed as part of, this Amendment No. 1 as Exhibits 12.1 and 13.1.

 

Other than expressly set forth herein, this Amendment No. 1 does not, and does not purport to, amend or restate any other information contained in the Original Filing nor does this Amendment No. 1 reflect any events that have occurred after the Original Filing was filed.

 

 

 

 

PART III

 

ITEM 17. FINANCIAL STATEMENTS

 

We have elected to provide financial statements and related information pursuant to Item 18.

 

ITEM 18. FINANCIAL STATEMENTS

 

The consolidated financial statements and the related notes required by this Item are included in this Amendment No.1 to our Annual Report on Form 20-F beginning on page F-1.

 

1

 

 

ITEM 19. EXHIBITS

 

        Incorporation by Reference
Exhibit No.   Exhibit Description   Form   File No.   Exhibit No.   Filing Date   Filed/
Furnished
1.1   Amended and Restated Articles of Association of SciSparc Ltd.     6-K     001-38041   99.1   June 26, 2025    
2.1#   Description of Securities                      
2.2   Form of Warrant to Purchase Ordinary Shares of SciSparc Ltd.   6-K   001-38041   4.2   February 12, 2026    
2.3   Form of Pre-Funded Warrant   6-K   001-38041   4.1   January 26, 2026    
4.1   Form of Indemnification Agreement   20-F   001-38041   4.12   May 1, 2017    
4.2   Form of Exculpation Agreement   20-F   001-38041   4.5   March 30, 2021    
4.3   Compensation Policy of SciSparc Ltd. for Executive Officers and Directors     6-K   001-38041   99.2   June 26, 2025    
4.4   License Agreement dated July 29, 2018, by and between the Company and Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.   20-F   001-38041   4.2   May 15, 2019    
4.5   Consulting Agreement, dated March 22, 2023, by and between Jeffs’ Brands Ltd and SciSparc Nutraceuticals Inc.   6-K   001-38041   10.3   April 4, 2023    
4.6   Standby Equity Purchase Agreement dated January 21, 2024, between YA II PN Ltd. and SciSparc Ltd.   6-K   001-38041   10.1   January 25, 2024    
4.7   First Amendment to the Standby Equity Purchase Agreement, dated as of February 26, 2024, between SciSparc Ltd. and YA II PN, Ltd   F-1   333-277394   10.22   February 27, 2024    
4.8   Israeli Share Option Plan       F-1   333-214458   10.5   November 4, 2016     
4.9   SciSparc Share Incentive Plan (2023)   F-1   333-277394   10.7   February 27, 2024    
4.10   Share Transfer Agreement, by and among Capital Point Ltd., Therapix Biosciences, Ltd. and Evero Health Ltd., dated May 15, 2020   6-K   001-38041   99.1   May 19, 2020    
4.12   Amendment to the Loan Agreement, dated June 9, 2024, by and between SciSparc Ltd. and Polyrizon Ltd.   F-1   333-277394   10.25   June 17, 2024    
4.13   Exclusive Patent License Agreement, dated August 13, 2024, between SciSparc Ltd. and Polyrizon Ltd.   6-K   001-38041   10.1   August 19, 2024    
4.14   Securities Purchase Agreement between SciSparc Ltd. and YA II PN, Ltd.   6-K   001-38041   10.2   February 27, 2025    
4.15   Global Guaranty Agreement, dated February 25, 2025, by Brain Bright Ltd. and Evero Health Ltd. in favor of an investor.   6-K   001- 38041   10.3   February 27, 2025    
4.16   Securities Purchase and Exchange Agreement, dated February 25, 2025, by and among N2OFF, Inc., MitoCareX Bio Ltd., SciSparc Ltd., Dr. Alon Silberman and Prof. Ciro Leonardo Pierri.   6-K   001- 38041   10.1   March 3, 2025    
4.17   Framework Agreement, dated as of October 6, 2025, by and among SciSparc Ltd., SciSparc Merger Sub Ltd., and AutoMax Ltd.   6-K   001- 38041   99.1   October 6, 2025    
4.18   Asset and Share Purchase Agreement, dated as of October 9, 2025, by and between SciSparc Ltd. and Miza III Ventures Inc.   6-K   001- 38041   10.1   October 15, 2025    

 

2

 

 

4.19   Binding Term Sheet for the Sale of Patent Portfolio and Trademarks by and between SciSparc Ltd. and Xylo Technologies Ltd. (November 26, 2025)   6-K   001- 38041   10.1   November 26, 2025    
4.20   Form of Securities Purchase Agreement, dated November 27, 2025, by and between the Company and the purchaser parties thereto   6-K   001- 38041   10.1   November 28, 2025    
4.21   Securities Purchase Agreement, dated February 12, 2026, by and between SciSparc Ltd. and L.I.A. Pure Capital Ltd.   6-K   001-38041   10.1   February 12, 2026    
4.22   Side Letter to Securities Purchase Agreement, dated February 12, 2026, by and between SciSparc Ltd. and L.I.A. Pure Capital Ltd.   6-K   001-38041   10.1   February17, 2026    
4.23   Form of Convertible Promissory Note   6-K   001-38041   4.1   February 12, 2026    
4.24   Asset Purchase Agreement, Dated January 8, 2026, by and between Xylo Technologies Ltd. and SciSparc Ltd.   6-K   001-38041   10.1   January 13, 2026    
4.25#   Share Purchase Agreement, dated March 9, 2026, by and between Shareholders of CliniQuantum Ltd., CliniQuantum Ltd. and NeuroThera Labs Inc.                    
8.1   List of Subsidiaries    F-1   333-281821   21.1   December 23, 2025    
11.1#   Insider Trading Policy                    
12.1*   Certification of the Chief Executive Officer and Chief Financial Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934.                   *
13.1**   Certification of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. 1350.                   **
15.1*   Consent of Kost Forer Gabbay & Kasierer, a member of EY Global, independent registered accounting firm for the Registrant.                   *
15.2*   Consent of Brightman Almagor Zohar & Co., a firm in the Deloitte Global Network.                   *
97.1   Clawback Policy   20-F   001-38041   97.1   April 1, 2024    
101 INS   Inline XBRL Instance Document.                    
101.SCH   Inline XBRL Taxonomy Extension Schema Document.                    
101 CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document                    
101 DEF   Inline XBRL Taxonomy Definition Linkbase Document.                    
101 LAB   Inline XBRL Taxonomy Extension Label Linkbase Document.                    
101 PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document                    
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).                    

 

* Filed herewith
** Furnished herewith.
# Previously Filed

 

3

 

 

SIGNATURES

 

The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this Amendment No. 1 to its Annual Report on Form 20-F filed on its behalf.

 

SCISPARC LTD.  
     
By: /s/ Oz Adler  
  Oz Adler  
  Chief Executive Officer  

 

Date August 19, 2026 

 

4

 

 

SCISPARC LTD. AND ITS SUBSIDIARIES

 

CONSOLIDATED FINANCIAL STATEMENTS

 

AS OF DECEMBER 31, 2025

 

U.S. DOLLARS IN THOUSANDS

 

INDEX

 

    Page
Report of Independent Registered Public Accounting Firm (PCAOB ID 1197)   F-2 - F-3
     
Report of Independent Registered Public Accounting Firm (PCAOB ID 1281)   F-4
     
Consolidated Statements of Financial Position   F-5 - F-6
     
Consolidated Statements of Comprehensive Loss   F-7
     
Consolidated Statements of Changes in Equity   F-8
     
Consolidated Statements of Cash Flows   F-9 - F-11
     
Notes to Consolidated Financial Statements   F-12 - F-51

 

F-1

 

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the shareholders and the Board of Directors of SciSparc Ltd.

 

Opinion on the Financial Statements

 

We have audited the accompanying consolidated statement of financial position of SciSparc Ltd. and its subsidiaries (the “Company”) as of December 31, 2025, the related consolidated statements of comprehensive loss, changes in equity and cash flows for the year then ended, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025, and the results of its operations and its cash flows for the year then ended, in conformity with IFRS Accounting Standards as issued by the International Accounting Standards Board (IASB).

 

Going Concern

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1B to the financial statements, the Company’s accumulated losses and additional funds needed to maintain its operations raise substantial doubt about its ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 1B. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Basis for Opinion

 

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

 

Critical Audit Matter

 

The critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that was communicated or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

 

F-2

 

 

Revenue recognition — Refer to Note 2t to the Consolidated Financial Statements

 

Critical Audit Matter Description

 

The Company recognizes revenue from product sales through Amazon’s Fulfillment by Amazon (“FBA”) platform. Revenue is recognized when control of the product transfers to the customer, net of estimated returns. The Company uses Amazon-generated reports and settlement statements to record revenue and reconcile sales and collection activity.

 

We identified revenue recognized for FBA-channel sales as a critical audit matter because of the use of third-party reports in the recording of revenues and reconciliation of sales and collection activity. This required an increased extent of effort, in relation to our audit as whole, when auditing the occurrence assertion for FBA-channel revenue.

 

How the Critical Audit Matter Was Addressed in the Audit

 

Our audit procedures related to the occurrence assertion of FBA-channel revenue included, among others:

 

We agreed FBA-channel revenue to underlying Amazon orders and delivery reports.

 

We tested the Company’s inventory roll-forward and agreed the underlying quantities of product sales to the Company’s recorded revenue.

 

We agreed cash received in bank to Amazon settlement statements and to the respective recorded revenue.

 

/s/ Brightman Almagor Zohar & Co.

Brightman Almagor Zohar & Co.

Certified Public Accountants

A Firm in the Deloitte Global Network

 

Tel Aviv, Israel

April 29, 2026

We have served as the Company’s auditor since 2026.

 

F-3

 

 

Kost Forer Gabbay & Kasierer
144 Menachem Begin Road,
Tel-Aviv 6492102, Israel
Tel: +972-3-6232525
Fax: +972-3-5622555
ey.com

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Shareholders and the Board of Directors of

 

SCISPARC LTD. AND ITS SUBSIDIARIES

 

Opinion on the Financial Statements

 

We have audited the accompanying consolidated statement of financial position of SciSparc Ltd. and its subsidiaries (the “Company”) as of December 31, 2024, the related consolidated statements of comprehensive loss, changes in equity and cash flows for each of the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2024, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024, in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board.

 

The Company’s Ability to Continue as a Going Concern

 

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has suffered recurring losses from operations, negative cash flows from operating activities, and has stated that substantial doubt exists about the Company’s ability to continue as a going concern. Management’s evaluation of the events and conditions and management’s plans regarding these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Basis for Opinion

 

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

/s/ KOST FORER GABBAY & KASIERER   Tel Aviv, Israel
A Member of EY Global   April 24, 2025, (except for Note 1(d), as to which the date is July 8, 2025)

 

We served as the Company’s auditor from 2007 to 2025.

 

F-4

 

 

SCISPARC LTD. AND ITS SUBSIDIARIES

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

 

      December 31, 
      2025   2024 
   Note  USD in thousands 
ASSETS           
            
CURRENT ASSETS:           
Cash and cash equivalents  4  $4,591   $1,540 
Restricted deposit      20    20 
Trade receivables      10    10 
Other accounts receivable  6   289    1,079 
Investments in short-term financial assets  24g   
-
    517 
Current maturities of long-term loan  8c   451    
-
 
Loans to a related party  8c   
-
    4,224 
Inventory  5   75    113 
              
       5,436    7,503 
              
NON-CURRENT ASSETS:             
              
Intangible assets, net  11   1,170    1,479 
Investments in an associate accounted for under the equity method  7   
-
    952 
Investments in financial assets  8, 24d   997    354 
Property and equipment, net  10   19    59 
              
       2,186    2,844 
              
      $7,622   $10,347 

 

The accompanying notes are an integral part of the consolidated financial statements.

 

F-5

 

 

SCISPARC LTD. AND ITS SUBSIDIARIES

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

 

      December 31, 
      2025   2024 
   Note  USD in thousands 
LIABILITIES AND EQUITY           
            
CURRENT LIABILITIES:           
Trade payables  12  $783   $816 
Other payables  13   270    242 
Related parties  24a   504    
-
 
Current maturities of long-term loans  25b   356    
-
 
Accrued legal contingency  17e   340    341 
              
       2,253    1,399 
              
NON-CURRENT LIABILITIES:             
Related party  24a   222    
-
 
Lease liability, excluding current portion  9   
-
    9 
              
       222    9 
              
       2,475    1,408 
EQUITY:  18          
Share capital and premium      76,481    70,886 
Reserve from share-based payment transactions  19   6,613    5,746 
Warrants      5,190    5,190 
Other reserves  2d,25   1,907    497 
Transactions with non-controlling interests  25   1,202    810 
Accumulated deficit      (87,154)   (74,975)
Equity attributable to owners of the Company      4,239    8,154 
Non-controlling interests      908    785 
              
Total equity      5,147    8,939 
              
Total liabilities and equity     $7,622   $10,347 

 

The accompanying notes are an integral part of the consolidated financial statements.

 

F-6

 

 

SCISPARC LTD. AND ITS SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

 

        Year ended December 31,  
        2025     2024     2023  
    Note   USD in thousands (except per share data)  
Revenues     2t   $ 856     $ 1,306     $ 2,879  
                               
Cost of revenues     20     225       800       683  
                               
Gross profit           631       506       2,196  
                               
Research and development expenses     21a     2,097       1,707       1,641  
Sales and marketing     21b     912       1,515       2,484  
Impairment of intangible assets           115       1,344       1,042  
General and administrative expenses     21c     6,371       4,526       3,844  
Other income, net     21d     (490 )     (1,270 )    
-
 
                               
Operating loss           8,374       7,316       6,815  
                               
Equity losses of an associate     7     500       429       210  
                               
Gain from sale of an associate     7     (2,231 )    
-
     
-
 
                               
Finance income     21e     (2,278 )     (612 )     (2,219 )
                               
Finance expenses     21f     8,199       353       1,055  
                               
Loss before income taxes           12,564       7,486       5,861  
                               
Taxes on income          
-
      (14 )     22  
                               
Net loss and total comprehensive loss           12,564       7,472       5,883  
                               
Attributable to:                              
Equity holders of the Company           12,179       6,284       5,122  
                               
Non-controlling interests           385       1,188       761  
                               
            12,564       7,472       5,883  
                               
Basic and diluted loss per ordinary share attributable to equity holders of the Company (*):     22     98.07       203.89       2,374.55  

 

(*)Share and per share data in these consolidated financial statements have been retrospectively adjusted, for all periods presented, to reflect a number of shares that is equivalent to the number of shares of the Company post the Fifth Reverse Share Split (see note 18a).

 

The accompanying notes are an integral part of the consolidated financial statements.

 

F-7

 

 

SCISPARC LTD. AND ITS SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

 

   Attributable to equity holders of the Company         
   Share
capital
and
premium
   Reserve
from share-
based
payment
transactions
   Warrants   Transactions
with non-
controlling
interests
   Other
reserves
   Accumulated
deficit
   Total   Non-
controlling
interests
   Total
equity
 
   USD in thousands 
Balance at January 1, 2023  $58,592   $5,180   $5,190   $559   $497   $(63,569)  $6,449   $
-
   $6,449 
                                              
Net loss   
-
    
-
    
-
    
-
    
-
    (5,122)   (5,122)   (761)   (5,883)
Sale of non-controlling interest in subsidiary   
-
    
-
    
-
    251    
-
    
-
    251    2,734    2,985 
Issuance of ordinary shares in respect of investment in associate   288    
-
    
-
    
-
    
-
    
-
    288    
-
    288 
Issuance of ordinary shares, net of issue expenses   5,552    
-
    
-
    
-
    
-
    
-
    5,552    
-
    5,552 
Cost of share-based payment   94    102    
-
    
-
    
-
    
-
    196    
-
    196 
                                              
Balance at December 31, 2023  $64,526   $5,282   $5,190   $810   $497   $(68,691)  $7,614   $1,973   $9,587 
                                              
Net loss   
-
    
-
    
-
    
-
    
-
    (6,284)   (6,284)   (1,188)   (7,472)
Issuance of ordinary shares, net of issue expenses   6,255    
 
    
 
    
 
    
 
    
-
    6,255    
-
    6,255 
Cost of share-based payment   105    464    
-
    
-
    
-
    
-
    569    
-
    569 
Balance at December 31, 2024  $70,886   $5,746   $5,190   $810   $497   $(74,975)  $8,154   $785   $8,939 
                                              
Net loss   
-
    
-
    
-
    
-
    
-
    (12,179)   (12,179)   (385)   (12,564)
                                              
Issuance of ordinary shares, net of issue expenses (note 18k)   2,262    
-
    
-
    
-
    
-
    
-
    2,262    
-
    2,262 
Issuance and exercise of warrants (note 18j)   1,121    
-
    
-
    
-
    
-
    
-
    1,121    
-
    1,121 
Issuance and conversion of convertible debentures (note 18i)    2,212    
-
    
-
    
-
    
-
    
-
    2,212    
-
    2,212 
Deemed issuance of shares by a subsidiary (note 25)   
-
    
-
    
-
    392    
-
    
-
    392    187    579 
Deemed stock exchange listing expenses (note 25)   
-
    
-
    
-
    
-
    1,410    
-
    1,410    
-
    1,410 
Cost of subsidiaries share-based payment (note 25)   
-
    
-
    
-
    
-
    
-
    
-
    
-
    321    321 
Cost of share-based payment   
-
    867    
-
    
-
    
-
    
-
    867    
-
    867 
Balance at December 31, 2025  $76,481   $6,613   $5,190   $1,202   $1,907   $(87,154)  $4,239   $908   $5,147 

 

The accompanying notes are an integral part of the consolidated financial statements.

 

F-8

 

 

SCISPARC LTD. AND ITS SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

 

   Year ended December 31, 
   2025   2024   2023 
   USD in thousands 
Cash flows from operating activities:            
             
Net loss  $(12,564)  $(7,472)  $(5,883)
                
Adjustments to reconcile loss to net cash used in operating activities:               
                
Adjustments to the profit or loss items:               
                
Depreciation and amortization   234    482    538 
Impairment of an intangible asset   115    1,344    1,042 
Cost of share-based payment   867    569    196 
Impairment of loan (see note 8c)   5,973    
-
    
-
 
Subsidiaries’ cost of share-based payment (see note 25)   321    
-
    
-
 
Finance income, net   (1,998)   (897)   (2,205)
Equity losses   500    429    210 
Deemed stock exchange listing expense   1,410    
-
    
-
 
Gain on sale of an associate accounted for under the equity method   (2,231)   
-
    
-
 
Losses from remeasurement of investment in financial assets   1,791    305    1,048 
                
    6,982    2,232    829 
                
Working capital adjustments:               
                
Decrease in trade receivables   
-
    12    55 
Decrease (increase) in other accounts receivable   790    (535)   (409)
Decrease (increase) in inventory   38    629    (74)
Increase (decrease) in trade payables   (164)   25    (397)
Increase (decrease) in other payables   55    20    (8)
Increase (decrease) in related parties   726    (15)   
-
 
                
    1,445    136    (833)
                
Net cash used in operating activities  $(4,137)  $(5,104)  $(5,887)

 

The accompanying notes are an integral part of the consolidated financial statements.

 

F-9

 

 

SCISPARC LTD. AND ITS SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

 

   Year ended December 31, 
   2025   2024   2023 
   USD in thousands 
Cash flows from investing activities:            
             
Withdrawal of (investment in) restricted bank deposits  $
-
   $45   $(5)
Withdrawal of (investment in) short-term bank deposits   
-
    3,000    (3,000)
Sale of property and equipment   
-
    8    
-
 
Investment in an associate accounted for under the equity method   (100)   (600)   (400)
Loan to related parties   (2,000)   (4,078)   
-
 
Investments in financial assets   
-
    
-
    (689)
Proceeds from sale of an affiliate accounted for under the equity method (see note 7)   700    
-
    
-
 
                
Net cash used in investing activities   (1,400)   (1,625)   (4,094)
                
Cash flows from financing activities:               
                
Proceeds from issuance of share capital (net of issuance expenses)   2,262    6,255    5,552 
Proceeds from exercise of warrants   1,121    
-
    
-
 
Sale of non-controlling interest in a subsidiary   
-
    
-
    2,985 
Repayment of loans   192    
-
    
-
 
Receipt of loans   356    
-
    
-
 
Proceeds from deemed issuance of shares by a subsidiary (see (b) below)   710    
-
    
-
 
Proceeds from issuance of convertible debentures (see note 18i)   3,990    
-
    
-
 
Interest paid on lease liability   (5)   (8)   (7)
Repayment of lease liability   (38)   (54)   (47)
                
Net cash provided by financing activities   8,588    6,193    8,483 
                
Increase (decrease) in cash   3,051    (536)   (1,498)
Cash at the beginning of the period   1,540    2,076    3,574 
                
Cash at the end of the period  $4,591   $1,540   $2,076 

 

The accompanying notes are an integral part of the consolidated financial statements.

 

F-10

 

 

SCISPARC LTD. AND ITS SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

 

   Year ended December 31, 
   2025   2024   2023 
   USD in thousands 
(a) Significant non-cash financing and investing activities:            
             
Right-of-use asset recognized with corresponding lease liability   
-
    75    102 
                
Investment in financial asset   
-
    
-
    288 
Exchange of MitoCareX shares with Nexentis Inc. shares (see Note 7)   2,027    
-
    
-
 

Conversion of convertible debentures

   2,212    
-
    
-
 

 

(b) Assets and liabilities received as consideration for deemed issuance of shares by a subsidiary    
   As of
October 22,
2025
 
Consolidation of NeuroThera (as described in Note 1a)    
Trade payables   (131)
Net assets received as consideration for deemed issuance of shares by a subsidiary   (579)
      
Cash received as consideration for deemed issuance of shares by a subsidiary   (710)

 

The accompanying notes are an integral part of the consolidated financial statements.

 

F-11

 

 

SCISPARC LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

USD in thousands (except share data)

 

NOTE 1:- GENERAL

 

  a. SciSparc Ltd. (formerly known as Therapix Biosciences Ltd.) (“SciSparc” or the “Company” or the “Group”), a clinical-stage pharmaceutical company, was incorporated in Israel and commenced its operations on August 23, 2004. Until March 2014, SciSparc and its subsidiaries at the time were mainly engaged in developing several innovative immunotherapy products and SciSparc’s own patents in the immunotherapy field. In August 2015, the Company decided to adopt a different business strategy and began focusing on developing a portfolio of approved drugs based on cannabinoid molecules. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company, through its subsidiary NeuroThera Labs Inc. (formerly known as Miza III Ventures Inc.) (TSXV:NTLX) (“NeuroThera”), is currently engaged in the following drug development programs based on Δ9-tetrahydrocannabinol (“THC”) and/or non-psychoactive cannabidiol for the treatment of Tourette syndrome, Alzheimer’s disease and agitation; and SCI-210 for the treatment of autism spectrum disorder and status epilepticus. The Company, through NeuroThera, also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on the Amazon Marketplace.

 

The Company’s ordinary shares, no par value per share (“ordinary shares”), are listed on Nasdaq and are trading under the symbol “SPRC”.

 

As of December 31, 2025, the Company has a controlling interest in NeuroThera, a publicly traded company on the TSX Venture Exchange (the “TSXV”) in Canada, Evero Health Ltd. (“Evero”) and Brain Bright Ltd. (“Brain Bright”), together, the “Subsidiaries. Also, as of December 31, 2025, the Company holds 75% of the outstanding shares of NeuroThera (see note 25).

 

Evero and Brain Bright are inactive Israeli incorporated companies.

 

On July 3, 2025, the Company effected a one-for-twenty one (1-for-21) reverse share split of the issued and outstanding ordinary shares. On February 5, 2026, the Company effected a one-for-nine (1-for-9) reverse share split (the “Fifth Reverse Share Split”) of the issued and outstanding ordinary shares. Consequently, all share and per share data included in these financial statements for all periods preceding the effective dates of the reverse share splits have been adjusted to reflect the reverse splits’ ratios in these consolidated financial statements for all periods presented. See note 18.

 

b.The Group incurred operating losses since its incorporation and expects to continue to incur operating losses for the foreseeable future. As of December 31, 2025, the Group had an accumulated deficit of approximately $87,154 as a result of recurring operating losses.

 

As of December 31, 2025, the Company’s cash and cash equivalents totaled $4,591. For the year ended December 31, 2025, the Company had an operating loss of $8,374 and negative cash flows from operating activities of $4,137. The Company’s current cash and cash equivalents position is not sufficient to fund the Company’s planned operations for at least a year beyond the filing date of the financial statements. The ability to continue as a going concern is dependent upon the Company obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they become due. While the Company has successfully raised funds in the past, there is no guarantee that it will be able to do so in the future. The above-mentioned factors raise substantial doubt about the Group’s ability to continue as a going concern.

 

The accompanying consolidated financial statements were prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liabilities and commitments in the normal course of business. Such financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to the Company’s ability to continue as a going concern.

 

F-12

 

 

SCISPARC LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

USD in thousands (except share data)

 

NOTE 1:- GENERAL (CONT.)

 

c. Definitions and Meanings:

 

  The Company - SciSparc Ltd. (formerly known as Therapix Biosciences Ltd.)
       
  The Group - SciSparc Ltd. (formerly Therapix Biosciences Ltd.) and its Subsidiaries, as detailed in Note 1a.
       
  SNI - SciSparc Neutraceuticals Inc.
       
  Subsidiaries - Companies that are controlled by the Company, as defined in IFRS 10, “Consolidated Financial Statements”, and whose accounts are consolidated with those of the Company.
       
  Associate - An entity over which the Company has significant influence, as defined in IAS 28, “Investment in Associates and Joint Ventures” and is not a Subsidiary.
       
  Related Parties - As defined in IAS 24, “Related Party Disclosures”.
       
  IAS - International Accounting Standards issued by the International Accounting Standards Board (“IASB”).
       
  IFRS - International Financial Reporting Standards issued by the IASB.

 

  d. On July 3, 2025, the Company effected a twenty one-for-one reverse share split of its ordinary shares. All share and per share information has been retroactively adjusted to reflect the reverse share split for all periods presented.

 

NOTE 2:- MATERIAL ACCOUNTING POLICIES

 

The following accounting policies have been applied consistently in the consolidated financial statements for all periods presented, unless otherwise stated.

 

  a. Basis of presentation of the financial statements:

 

The consolidated financial statements have been prepared in accordance with IFRS Accounting Standards and their interpretations, which were issued by the IASB.

 

The Company’s financial statements have been prepared on a cost basis, unless otherwise indicated.

 

The consolidated financial statements are presented in USD and all values are rounded to the nearest thousand (’000), except when otherwise indicated.

 

  b. The operating cycle:

 

The operating cycle of the Company is one year.

 

F-13

 

 

SCISPARC LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

USD in thousands (except share data)

 

NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES (CONT.)

 

  c. Consolidated financial statements:

 

The consolidated financial statements comprise the financial statements of companies that are controlled by the Company (Subsidiaries). Control of a company is achieved when the Company is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee. Potential voting rights are considered when assessing whether an entity has control over the other entity. The consolidation of the financial statements commences on the date on which control is obtained and ends when such control ceases.

 

The consolidated financial statements of the Company and of the Subsidiaries are prepared as of the same dates and periods. The consolidated financial statements are prepared using uniform accounting policies by all companies in the Group. Significant intra-Group balances and transactions and gains or losses resulting from intra-Group transactions are eliminated in full in the consolidated financial statements.

 

Non-controlling interests in subsidiaries represent the equity in subsidiaries not attributable, directly or indirectly, to a parent. Non-controlling interests are presented in equity separately from the equity attributable to the equity holders of the Company. Profit or loss and components of other comprehensive income are attributed to the Company and to non-controlling interests. Losses are attributed to non-controlling interests even if they result in a negative balance of non-controlling interests in the consolidated statement of financial position.

 

d. Functional currency and foreign currency:

 

The functional currency of the Company, which is the currency that best reflects the economic environment in which the Company operates and conducts its transactions is the U.S. Dollar (“USD” or “$”), since it’s the primary currency of the economic environment in which the Company operates. The consolidated financial statements are also presented in USD since the Company believes that preparing the consolidated financial statements in USD provides more relevant information to the users of the consolidated financial statements. Transactions and balances originally denominated in U.S. dollars are presented at their original amounts. Balances in non-U.S. dollar currencies are translated into U.S. dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-U.S. dollar transactions and other items in the statements of operations (indicated below), the following exchange rates are used: (i) for transactions exchange rates at transaction dates and (ii) for other items (derived from non-monetary balance sheet items such as depreciation and amortization) historical exchange rates. Currency transaction gains and losses are presented in the financial income net, as appropriate.

 

  e. Investment in joint arrangements:

 

Joint arrangements are arrangements in which the Company has joint control. Joint control is the contractually agreed sharing of control of an arrangement, which exists only when decisions about the relevant activities require the unanimous consent of the parties sharing control.

 

  f. Investments accounted for using the equity method:

 

The Group’s investments in associates and joint ventures are accounted for using the equity method.

 

Under the equity method, the investment in the associate or in the joint venture is presented at cost with the addition of post-acquisition changes in the Group’s share of net assets, including other comprehensive income of the associate or the joint venture. Gains and losses resulting from transactions between the Group and the associate or the joint venture are eliminated to the extent of the interest in the associate or in the joint venture. The cost of the investment includes transaction costs.

 

F-14

 

 

SCISPARC LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

USD in thousands (except share data)

 

NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES (CONT.)

 

  f. Investments accounted for using the equity method: (Cont.)

 

The consolidated financial statements of the Company and of the associate or joint venture are prepared as of the same dates and periods. The accounting policies applied in the financial statements of the associate or the joint venture are uniform and consistent with the policies applied in the consolidated financial statements of the Group.

 

The equity method is applied until the loss of significant influence in the associate or loss of joint control in the joint venture or classification as investment held for sale.

 

  g. Property and equipment, net:

 

Property and equipment are measured at cost, including directly attributable costs, less accumulated depreciation, accumulated impairment losses and any related investment grants and excluding day-to-day servicing expenses.

 

Depreciation is calculated on a straight-line basis over the useful life of the assets at annual rates as follows:

 

   %  Mainly % 
Lab equipment  6-50   33 
Computers  33-50   33 
Office furniture and equipment  7-15   15 
Leasehold improvements  see below   - 

 

Leasehold improvements are depreciated on a straight-line basis over the shorter of the lease term (including the extension option held by a company and intended to be exercised) and the expected life of the improvement.

 

  h. Intangible assets:

 

Separately acquired intangible assets are measured on initial recognition at cost including directly attributable costs. Intangible assets acquired in a business combination are measured at fair value at the acquisition date. Expenditures relating to internally generated intangible assets, excluding capitalized development costs, are recognized in profit or loss when incurred.

 

Intangible assets with a finite useful life are amortized over their useful life and reviewed for impairment whenever there is an indication that the asset may be impaired. The amortization period and the amortization method for an intangible asset are reviewed at least at each year-end.

 

  i. Impairment of non-financial assets:

 

The Company evaluates the need to record an impairment of non-financial assets whenever events or changes in circumstances indicate that the carrying amount is not recoverable. If the carrying amount of non-financial assets exceeds their recoverable amount, the assets are reduced to their recoverable amount. The recoverable amount is the higher of fair value less costs of sale and value in use. In measuring value in use, the expected future cash flows are discounted using a pre-tax discount rate that reflects the risks specific to the asset. The recoverable amount of an asset that does not generate independent cash flows is determined for the cash-generating unit to which the asset belongs. Impairment losses are recognized in profit or loss.

 

F-15

 

 

SCISPARC LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

USD in thousands (except share data)

 

NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES (CONT.)

 

  j. Financial instruments:

 

  1. Financial assets:

 

Financial assets are measured upon initial recognition at fair value plus transaction costs that are directly attributable to the acquisition of the financial assets, except for financial assets measured at fair value through profit or loss in respect of which transaction costs are recorded in profit or loss.

 

The Company classifies and measures debt instruments in the consolidated financial statements based on the following criteria:

 

  - The Company’s business model for managing financial assets; and

 

  - The contractual cash flow terms of the financial asset.

 

  a) Debt instruments are measured at amortized cost when:

 

The Company’s business model is to hold the financial assets in order to collect their contractual cash flows, and the contractual terms of the financial assets give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. After initial recognition, the instruments in this category are measured according to their terms at amortized cost using the effective interest rate method, less any provision for impairment.

 

On the date of initial recognition, the Company may irrevocably designate a debt instrument as measured at fair value through profit or loss if doing so eliminates or significantly reduces a measurement or recognition inconsistency, such as when a related financial liability is also measured at fair value through profit or loss.

 

  b) Equity instruments classified as fair value through profit and loss (“FVTPL”):

 

Investments in equity instruments are classified as at FVTPL, unless the group designates an equity investment that is neither held for trading nor a contingent consideration arising from a business combination as at fair value through other comprehensive income on initial recognition.

 

F-16

 

 

SCISPARC LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

USD in thousands (except share data)

 

NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES (CONT.)

 

  j. Financial instruments: (Cont.)

 

  2. Impairment of financial assets:

 

The Company evaluates at the end of each reporting period the loss allowance for financial debt instruments which are not measured at fair value through profit or loss. The Company distinguishes between two types of loss allowances:

 

  a) Debt instruments whose credit risk has not increased significantly since initial recognition, or whose credit risk is low - the loss allowance recognized in respect of this debt instrument is measured at an amount equal to the expected credit losses within 12 months from the reporting date (12-month ECLs); or

 

  b) Debt instruments whose credit risk has increased significantly since initial recognition, and whose credit risk is not low - the loss allowance recognized is measured at an amount equal to the expected credit losses over the instrument’s remaining term (lifetime ECLs).

 

The Company has short-term financial assets in respect of which the Company applies the simplified approach in IFRS 9 and measures the loss allowance in an amount equal to the lifetime expected credit losses.

 

The Company considers a financial asset in default when contractual payments are more than 180 days past due. However, in certain cases, the Company considers a financial asset to be in default when external or internal information indicates that the Company is unlikely to receive the outstanding contractual amounts in full.

 

  3. Financial liabilities:

 

  a) Financial liabilities measured at amortized cost:

 

Financial liabilities are initially recognized at fair value less transaction costs that are directly attributable to the issue of the financial liability.

 

After initial recognition, the Company measures all financial liabilities at amortized cost using the effective interest rate method, except for financial liabilities at fair value through profit or loss such as derivatives.

 

  b) Financial liabilities measured at fair value through profit or loss:

 

At initial recognition, the Company measures financial liabilities that are not measured at amortized cost at fair value. Transaction costs are recognized in profit or loss.

 

After initial recognition, changes in fair value are recognized in profit or loss.

 

F-17

 

 

SCISPARC LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

USD in thousands (except share data)

 

NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES (CONT.)

 

  j. Financial instruments: (Cont.)

 

  4. Compound financial instruments:

 

Convertible debentures which contain both an equity/derivative component and a liability component are separated into two components. This separation is performed by first determining the liability component based on the fair value of an equivalent non-convertible liability. The value of the conversion component is determined to be the residual amount. Directly attributable transaction costs are apportioned between the equity component and the liability component based on the allocation of proceeds to the equity and liability components.

 

  5. Issue of a unit of securities:

 

The issue of a unit of securities involves the allocation of the proceeds received (before issue expenses) to the securities issued in the unit based on the following order: financial derivatives and other financial instruments measured at fair value in each period. Then fair value is determined for financial liabilities that are measured at amortized cost. The proceeds allocated to equity instruments are determined to be the residual amount. Issue costs are allocated to each component pro rata to the amounts determined for each component in the unit.

 

  k. Research and development expenditures:

 

Research expenditures are recognized in profit or loss when incurred.

 

The conditions enabling capitalization of development costs as an asset have not yet been met and, therefore, all development expenditures are recognized in profit or loss when incurred.

 

  l. Finance income and expenses:

 

Finance income and expenses comprise interest income on amounts invested and exchange rate gains and losses. Interest income is recognized as it accrues using the effective interest method. Finance income and expenses derive also from changes in the fair value of financial liabilities measured at fair value through profit or loss. Borrowing costs are recognized in profit or loss using the effective interest method.

 

  m. Fair value measurement:

 

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurement is based on the assumption that the transaction will take place in the asset’s or the liability’s principal market, or in the absence of a principal market, in the most advantageous market.

 

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

 

Fair value measurement of a non-financial asset takes into account a market participant’s ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use.

 

F-18

 

 

SCISPARC LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

USD in thousands (except share data)

 

NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES (CONT.)

 

  m. Fair value measurement: (Cont.)

 

The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data is available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs.

 

All assets and liabilities measured at fair value or for which fair value is disclosed are categorized into levels within the fair value hierarchy based on the lowest level input that is significant to the entire fair value measurement:

 

  Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities.
       
  Level 2 - Inputs other than quoted prices included within Level 1 that are observable directly or indirectly.
       
  Level 3 - Inputs that are not based on observable market data (valuation techniques which use inputs that are not based on observable market data).

 

  n. Taxes on income:

 

Current or deferred taxes are recognized in profit or loss, except to the extent that they relate to items which are recognized in other comprehensive income or equity.

 

  1. Current taxes:

 

A current tax liability is measured using the tax rates and tax laws that have been enacted or substantively enacted by the reporting date as well as adjustments required in connection with the tax liability in respect of previous years.

 

  2. Deferred taxes:

 

Deferred taxes are computed in respect of temporary differences between the carrying amounts in the financial statements and the amounts attributed for tax purposes.

 

Deferred taxes are measured at the tax rate that is expected to apply when the asset is realized, or the liability is settled, based on tax laws that have been enacted or substantively enacted by the reporting date.

 

Deferred tax assets are reviewed at each reporting date and reduced to the extent that it is not probable that they will be utilized. Deductible carryforward losses and temporary differences for which deferred tax assets had not been recognized are reviewed at each reporting date and a respective deferred tax asset is recognized to the extent that their utilization is probable.

 

Deferred taxes are offset if there is a legally enforceable right to offset a current tax asset against a current tax liability and the deferred taxes relate to the same taxpayer and the same taxation authority.

 

F-19

 

 

SCISPARC LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

USD in thousands (except share data)

 

NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES (CONT.)

 

  o. Share-based payment transactions:

 

The Company’s employees and other service providers may receive remuneration in the form of share-based payments (“Equity-settled transactions”).

 

Equity-settled transactions:

 

The cost of equity-settled transactions with employees is measured at the fair value of the equity instruments granted at grant date. The fair value is determined using an acceptable option pricing model (“OPM”). As for service providers, the cost of the transactions is measured at the fair value of the goods or services received as consideration for equity instruments granted.

 

The cost of equity-settled transactions is recognized in profit or loss together with a corresponding increase in equity during the period in which the performance and/or service conditions are to be satisfied ending on the date on which the relevant employees become entitled to the award (the “Vesting Period”).

 

If a grant of an equity instrument is cancelled, it is accounted for as if it had vested on the cancellation date and any expense not yet recognized for the grant is recognized immediately. However, if a new grant replaces the cancelled grant and is identified as a replacement grant on the grant date, the cancelled and new grants are accounted for as a modification of the original grant, as described above.

  

  p. Earnings (loss) per share:

 

Earnings (loss) per share are calculated by dividing the income (loss) attributable to equity holders of the Company by the weighted number of ordinary shares outstanding during the period.

 

Basic loss per ordinary share includes only ordinary shares that were outstanding during the period.

 

Potential ordinary shares are included in the computation of diluted loss per ordinary share when their conversion increases loss per ordinary share from continuing operations.

 

F-20

 

 

SCISPARC LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

USD in thousands (except share data)

 

NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES (CONT.)

 

  q. Employee benefit liabilities:

 

The Company has several employee-benefit plans:

 

  1. Short-term employee benefits:

 

Short-term employee benefits are benefits that are expected to be settled wholly before twelve months after the end of the annual reporting period in which the employees render the related services. These benefits include salaries, paid annual leave, paid sick leave, recreation and social security contributions and are recognized as expenses as the services are rendered. A liability in respect of a cash bonus or a profit-sharing plan is recognized when the Company has a legal or constructive obligation to make such payment as a result of past service rendered by an employee and a reliable estimate of the amount can be made.

 

  2. Post-employment benefits:

 

The plans are normally financed by contributions to insurance companies and classified as defined contribution plans or as defined benefit plans.

 

The Company has defined contribution plans to its employees according to the specific laws per country.

 

  r. Provisions:

 

A provision in accordance with IAS 37, “Provisions, Contingent Liabilities and Contingent Assets”, is recognized when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. When the Company expects part or all of the expense to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset but only when the reimbursement is virtually certain. The expense is recognized in the statement of profit or loss net of any reimbursement.

   

Following are the types of provisions included in the financial statements:

 

Legal claims:

 

A provision for claims is recognized when the Company has a present legal or constructive obligation as a result of a past event, it is more likely than not that an outflow of resources embodying economic benefits will be required by the Company to settle the obligation and a reliable estimate can be made of the amount of the obligation.

 

Government grants:

 

Government grants received from the Israel Innovation Authority (“IIA”) are recognized upon receipt as a liability if future economic benefits are expected from the research project, that will result in royalty-bearing sales.

 

If no economic benefits are expected from the research activity, the grant received is recognized as a reduction of the related research and development expenses. In that event, the royalty obligation is treated as a contingent liability in accordance with IAS 37.

 

At each reporting date, the Company evaluates whether there is reasonable assurance that the liability recognized, in whole or in part, will not be repaid (as the Company will not be required to pay royalties) based on the best estimate of future sales and using the original effective interest method.

 

F-21

 

 

SCISPARC LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

USD in thousands (except share data)

 

NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES (CONT.)

 

  s. Inventories

 

Inventories are stated at the lower of cost and net realizable value. Inventories are adjusted for estimated excess and obsolescence and written down to net realizable value based upon estimates of future demand, technology developments, and market conditions. Cost is determined in accordance with first-in, first-out Method (“FIFO”) and the cost of inventory includes shipment and freight costs.

 

  t. Revenue recognition

 

The Company’s sells products directly to customers mainly through the Brand’s online Amazon stores (see note 11).

 

Under the Company’s standard contract terms, customers have a right of return within 30 to 90 days. For contracts with rights of return, the Company recognizes revenue based on the amount of the consideration which the Company expects to receive for products which it is highly probable that a significant revenue reversal will not subsequently occur. The Company recognizes a refund liability for consideration received or receivable if it expects to refund some or all of the consideration to the customer. At the end of each reporting period, the Company updates its estimates of expected product returns and adjusts the refund liabilities with a corresponding adjustment in revenues. As of December 31, 2025, the allowance for returns was immaterial. The refund liability is recorded as a decrease in revenues against other payables. A right of return asset and corresponding adjustment to cost of sales is also recognized for the right to recover the goods from the customer.

 

In certain contracts, the Company evaluates the nature of its promise to the customer and determines whether it is the principal or agent for each contract. In determining the nature of its promise to the customer, the Company evaluates whether it is appropriate to recognize revenues on a gross or net basis based upon its evaluation of whether the Company obtains control of the specified goods by considering if it is primarily responsible for fulfillment of the promise, has inventory risk, and has the latitude in establishing pricing and selecting suppliers, among other factors. Based on its evaluation of these factors, management has determined that it is the principal in these arrangements; therefore, revenues are recorded on a gross basis.

 

  u. Cost of revenues

 

Cost of revenues primarily consist of expenses related to direct costs and freight.

 

  v.

Sales and marketing expenditures

 

Selling and marketing and expenses consist of online retailer services (including shipping and handling costs), warehouse costs and online advertising costs (i.e. sales and distribution variable expenses). Selling and marketing expenses are expensed as incurred.  

 

w.

Cash and cash equivalents

 

In the consolidated statements of financial position, cash and bank balances comprise cash (i.e., cash on hand and demand deposits) and cash equivalents. Cash equivalents are short-term (generally with original maturity of three months or less), highly liquid investments that are readily convertible to a known amount of cash and which are subject to an insignificant risk of changes in value. Cash equivalents are held for the purpose of meeting short-term cash commitments rather for investment or other purposes.

 

Bank balances for which use by the Group is subject to third party contractual restrictions are included as part of cash unless the restrictions result in a bank balance no longer meeting the definition of cash. If the contractual restrictions to use the cash extend beyond 12 months after the end of the reporting period, the related amounts are classified as non-current in the statement of financial position.

 

For the purposes of the consolidated statements of cash flows, cash and cash equivalents consist of cash and cash equivalents as defined above.

 

  x. Disclosure of new standards in the period prior to their adoption

 

IFRS 18, “Presentation and Disclosure in Financial Statements”:

 

In April 2024, the IASB issued IFRS 18, “Presentation and Disclosure in Financial Statements” (“IFRS 18”) which replaces IAS 1, “Presentation of Financial Statements”.

 

As noted, IFRS 18 replaces IAS 1, carrying forward many of the requirements in IAS 1 unchanged and complementing them with new requirements. In addition, some paragraphs from IAS 1 have been moved to IAS 8 and IFRS 7. Furthermore, the IASB has made minor amendments to IAS 7 and IAS 33, “Earnings per Share”.

 

F-22

 

 

SCISPARC LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

USD in thousands (except share data)

 

NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES (CONT.)

 

  x. Disclosure of new standards in the period prior to their adoption (Cont.)

 

IFRS 18 introduces new requirements to:

 

present specified categories and defined subtotals in the statement of profit or loss.

 

provide disclosures on management-defined performance measures (MPMs) in the notes to the financial statements; and

 

improve aggregation and disaggregation.

 

An entity is required to apply IFRS 18 for annual reporting periods beginning on or after January 1, 2027, with earlier application permitted. The amendments to IAS 7 and IAS 33, as well as the revised IAS 8 and IFRS 7, become effective when an entity applies IFRS 18. IFRS 18 requires retrospective application with specific transition provisions. The Company is currently evaluating the impact that application of IFRS 18 will have on its consolidated financial statements and related disclosures.

 

NOTE 3:- SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN THE PREPARATION OF THE FINANCIAL STATEMENTS

 

In the process of applying the significant accounting policies, the Company has made the following judgments which have the most significant effect on the amounts recognized in the financial statements:

 

    Estimates and assumptions:

 

The preparation of the financial statements requires management to make estimates and assumptions that have an effect on the application of the accounting policies and on the reported amounts of assets, liabilities, revenues and expenses. Changes in accounting estimates are reported in the period of the change in estimate.

 

The key assumptions made in the financial statements concerning uncertainties at the reporting date and the critical estimates computed by the Company that may result in a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below.

 

  - Legal claims:

 

In estimating the likelihood of outcome of legal claims filed or threatened to commence against the Company and/or its Subsidiaries and/or affiliates, the Company relies on its management’s best knowledge and estimations and where applicable, on the opinion of their legal counsels. These estimates are based, among others, on management’s familiarity of and proximity to the circumstances, and also on the legal counsels’ best professional judgment, taking into account the stage of proceedings and legal precedents in respect of the different issues. Since the outcome of the claims might be determined in courts and/or other quasi-judicial tribunals, the results could differ from these estimates.

 

  - Fair value of financial instruments:

 

When the fair values of financial assets and financial liabilities recorded in the statement of financial position cannot be derived from active markets, their fair value is determined using a variety of valuation techniques that include the use of valuation models. The inputs to these models are taken from observable markets where possible, but where this is not feasible, estimation is required in establishing fair values. The models are tested for validity by calibrating to prices from any observable current market transactions in the same instrument when available.

 

F-23

 

 

SCISPARC LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

USD in thousands (except share data)

 

NOTE 4:- CASH AND CASH EQUIVALENTS

 

   December 31, 
   2025   2024 
Cash for immediate withdrawal - in USD  $2,699   $1,383 
Cash for immediate withdrawal - in CAD   1,628    
-
 
Cash for immediate withdrawal - in NIS   264    157 
           
   $4,591   $1,540 

 

NOTE 5:- INVENTORY

 

   December 31, 
   2025   2024 
Goods in transit  $17   $9 
Finished goods   58    104 
           
   $75   $113 

 

NOTE 6:- OTHER ACCOUNTS RECEIVABLE

 

   December 31, 
   2025   2024 
Government authorities  $89   $78 
Other receivables   97    449 
Prepaid expenses   88    350 
Receivables in respect of downpayment on merger   
-
    187 
Related party   15    15 
           
   $289   $1,079 

 

NOTE 7:- INVESTMENT IN ASSOCIATES

 

MitoCareX Transaction

 

On March 10, 2022, the Company entered into a Founders and Investment Agreement with Dr. Alon Silberman (the “MitoCareX Agreement”). Pursuant to the MitoCareX Agreement, the Company invested an initial amount of $700 during 2022. As of December 31, 2022, the Company owned 31.48% of the outstanding shares of MitoCare X Bio Ltd. (“MitoCareX”).

 

On February 17, 2023, MitoCareX achieved its first milestone pursuant to the MitoCareX Agreement. As a result of MitoCareX meeting this milestone, the Company invested an additional $400 in MitoCareX and increased its share ownership in MitoCareX from 31.48% to 41.92%.

 

On November 25, 2023, MitoCareX achieved its second milestone pursuant to the MitoCareX Agreement. As a result of MitoCareX meeting this milestone, the Company invested an additional sum of $600 in MitoCareX and increased its share ownership in MitoCareX from 41.92% to 52.73%. Notwithstanding the above, the Company and MitoCareX agreed for the additional $600 installment to be deferred to March 25, 2024, and the $600 installment was paid on March 11, 2024.

 

On February 25, 2025, the Company entered into a securities purchase and exchange agreement with Nexentis Technologies Inc. (“Nexentis”, formerly known as “N2OFF, Inc.”) to sell its stake in the issued and outstanding shares of MitoCareX for $700 and 490,751 shares of common stock of Nexentis, representing 17.70% of the total outstanding shares of Nexentis on a fully diluted basis.

 

As a result of the sale of its holdings in MitoCareX, the Company recorded a gain from sale of an associate in the amount of $2,231 for the year ended December 31, 2025.

 

The investment in MitoCareX was accounted for as an equity method investment, in accordance with IAS 28, “Investment in Associates and Joint Ventures”. For the year ended December 31, 2025, the Company recorded equity losses from the investment in MitoCareX in the amount of $500 ($429 and $210 for the years ended December 31, 2024 and 2023, respectively).

 

F-24

 

 

SCISPARC LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

USD in thousands (except share data)

 

NOTE 7:- INVESTMENT IN ASSOCIATES (CONT.)

 

  a. MitoCareX Transaction (Cont.)

 

The table below summarizes the changes in carrying value of the investment in MitoCareX:

 

Balance at January 1, 2023  $591 
Investment following achievement of first milestone   400 
Equity losses from investment in MitoCareX   (210)
      
Balance at December 31, 2023  $781 
      
Investment following achievement of second milestone   600 
Equity losses from investment in MitoCareX   (429)
Balance at December 31, 2024  $952 
      
Equity losses from investment in MitoCareX  $(500)
Investment in 2025   43 
Sale of investment in MitoCareX   (495)
Balance at December 31, 2025  $
-
 

 

NOTE 8:- INVESTMENT IN FINANCIAL ASSETS

 

a.Clearmind

 

On November 17, 2022, the Company invested $1,500 in the initial public offering of Clearmind Medicine Inc. (“Clearmind”) and received 192 common shares of Clearmind, resulting in the Company holding 9.33% of share capital of Clearmind. As of December 31, 2025, the Company holds 192 common shares of Clearmind, representing a stake of less than 1% of the share capital of Clearmind, at a price of $1.81 per common share. For the year December 31, 2025, the Company recorded a loss on revaluation of the fair value of its investment in Clearmind in the amount of $11 (for the years ended December 31, 2024 and 2023 - $11 and $707, respectively).   

 

F-25

 

 

SCISPARC LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

USD in thousands (except share data)

 

NOTE 8:- INVESTMENT IN FINANCIAL ASSETS (CONT.)

 

b.AutoMax

 

On June 25, 2023, the Company entered into a share purchase agreement (the “Share Purchase Agreement”) with AutoMax Motors Ltd. (“AutoMax”), an Israeli company traded on the Tel Aviv Stock Exchange (“TASE”) and a parallel importer and distributor of vehicles in Israel, pursuant to which, at the closing and upon the terms and conditions set forth in the Share Purchase Agreement, the Company invested NIS 2,500 (approximately $689) in cash, in exchange for 5,000,000 ordinary shares of AutoMax (the “AutoMax Shares”) based on a price per share of NIS 0.05, representing a 4.82% of the share capital of AutoMax. As of December 31, 2025, there has been no significant change in the Company holdings in AutoMax’s shares since June 25, 2023. As of December 31, 2025, the listed share price of AutoMax on the TASE was NIS 0.108 (December 31, 2024 – NIS 0.184), and the Company has recorded a loss in its statements of comprehensive loss of $83 on its investment ($277 and $158 for the years ended December 31, 2024 and 2023, respectively).

 

c.AutoMax Bridge Loans and Terminated Merger Agreement

 

AutoMax Bridge Loans

 

On January 16, 2024, the Company entered, as a lender, into an agreement (the “Bridge Loan Agreement”) with AutoMax, pursuant to which AutoMax received from the Company a bridge loan (the “Bridge Loan”) in the amount of $1,400, further to the previously announced non-binding letter of intent for the Company to acquire AutoMax (the “AutoMax Acquisition”).

 

The Bridge Loan Agreement states that the principal amount of the Bridge Loan will bear interest at a rate of 7% per annum (or 9% per annum if the AutoMax acquisition is not consummated prior to the repayment date), compounded annually.

 

On June 9, 2024, the Company entered into an amendment (the “Amendment”) to the Bridge Loan Agreement with AutoMax. Pursuant to the Amendment, the Company extended an additional loan in the amount of $1,000 to AutoMax under terms similar to the Bridge Loan Agreement, bringing the total Bridge Loan amount to $2,400.

 

On September 5, 2024, the Company entered into a second amendment (the “Second Amendment”) to the Bridge Loan Agreement with AutoMax. Pursuant to the Second Amendment, the Company extended an additional loan in the amount of $1,850 to AutoMax under terms similar to the Bridge Loan Agreement, bringing the total Bridge Loan amount to $4,250.

 

Additional Loan Agreement

 

On February 27, 2025, the Company entered into a loan agreement with AutoMax where a $2,000 loan was provided (the “Additional Loan”). The Additional Loan bears an 8% annual interest rate and will be repaid in equal monthly installments of $50 and interest.

 

Terminated Merger Agreement

 

On April 10, 2024, the Company and AutoMax entered into an Agreement and Plan of Merger (the “Merger Agreement”), pursuant to which AutoMax’s shareholders and a third party were expected to own approximately 49.99% of the Company’s share capital, on a fully-diluted basis, subject to certain exceptions, and as further defined in the Merger Agreement, and the Company’s shareholders were expected to own approximately 50.01% of its share capital, on a fully-diluted basis, subject to certain exceptions.

 

During September 2025 and following an investigation by the Israeli Securities Authority and Israeli Police, three senior officials of AutoMax were arrested. Following these events, on October 6, 2025, the Company announced that it entered into a framework agreement with AutoMax to (i) mutually terminate the Merger Agreement; (ii) amend the terms of repayment of the Bridge Loan to be repaid in a one lump-sum payment on January 1, 2028; and (iii) amend the terms of repayment of the Additional Loan to be repaid in monthly installments starting on November 20, 2025, of $60 each and the interest of 8% per annum, compounded annually up to each actual payment date, in addition to the payment of all interest accrued on such loan from its effective date until November 20, 2025, in the sum of $114.

 

On October 24, 2025, AutoMax announced that an Israeli court decision, made on October 21, 2025, froze proceedings against AutoMax and appointed a trustee according to an application from local Israeli banks. Following these events, the Bridge Loan and Additional Loan became due immediately.

 

The Company has evaluated the probabilities of recovering the funds extended to AutoMax in respect of the Bridge Loan and the Additional Loan and has determined that there is a 90% probability that the Bridge Loan and the Additional Loan will not be repaid to the Company. Accordingly, the Company recognized a loss on impairment of the loans in the amount of $5,973. As of December 31, 2025, the Bridge Loan and the Additional Loan amounts and accrued interest amounted to $451.

 

F-26

 

 

SCISPARC LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

USD in thousands (except share data)

 

NOTE 9:- LEASES

 

On April 1, 2024, the Company entered into a two-year lease agreement for a total area of approximately 240 square meters, whereby the Company occupies approximately 120 square meters for the Company’s offices, in the district of Tel Aviv, Israel. The Company has an option to extend for an additional three-year term. The monthly lease fee was set at approximately $3, linked to the NIS. On January 1, 2026, the Company exercised the option to extend the lease agreement until March 31, 2028.

 

NOTE 10:- PROPERTY AND EQUIPMENT, NET

 

   Computers   Office
furniture
and
equipment
   Right of
use asses
   Total 
Cost:                
Balance at January 1, 2025  $12    12    75    99 
Additions   
-
    1    
-
    1 
Disposals   
-
    
-
    
-
    
-
 
                     
Balance at December 31, 2025   12    13    75    100 
                     
Accumulated depreciation:                    
Balance at January 1, 2025   9    3    28    40 
Depreciation   1    1    39    41 
Disposals   
-
    
-
    
-
    
-
 
                     
Balance at December 31, 2025   10    4    67    81 
                     
Depreciated cost at December 31, 2025   2    9    8    19 
                     
Balance at January 1, 2024  $11    33    181    225 
Additions   2    
-
    75    77 
Disposals   (1)   (21)   (181)   (203)
                     
Balance at December 31, 2024   12    12    75    99 
                     
Accumulated depreciation:                    
Balance at January 1, 2024   6    6    106    118 
Depreciation   4    1    28    33 
Disposals   (1)   (4)   (106)   (111)
                     
Balance at December 31, 2024   9    3    28    40 
                     
Depreciated cost at December 31, 2024   3    9    47    59 

 

Depreciation expenses for the years ended December 31, 2025, 2024 and 2023 amounted to $41, $33 and $52, respectively.

 

NOTE 11:- INTANGIBLE ASSET

 

On September 30, 2022, the Company announced the closing of the acquisition of WellutionTM, an Amazon.com Marketplace seller account (the “Brand”), American food supplements and cosmetics brand and trademark (the “Acquisition”). In connection with the Acquisition, the Company incorporated a new wholly owned Delaware subsidiary, SciSparc Nutraceuticals Inc. (“SNI”), to hold the new assets.

 

F-27

 

 

SCISPARC LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

USD in thousands (except share data)

 

NOTE 11:- INTANGIBLE ASSET (CONT.)

 

The Company reviewed the transaction and deemed it to be the purchase of assets for accounting purposes under generally accepted accounting principles. The Company reviewed the guidance under IFRS 3 for the transaction and determined that the fair value of the gross assets acquired was concentrated in a single identifiable asset, a brand. Accordingly, the Company treated the transaction as an asset acquisition. On the closing date of the acquisition, the Company fully recognized the acquisition amount total of $4,861 as an intangible asset, to be amortized over a period of 10 years.

 

For the years ended December 31, 2023, 2024 and 2025, the Brand recorded significant losses. As of December 31, 2025, the Company has determined there are signs of decline in the value of the Brand and recognized a loss as a result of impairment to its intangible asset of $115 (as of December 31, 2024 - $1,344, as of December 31, 2023 - $1,042).

 

The table below summarizes the carrying value of the intangible asset:

 

Balance at January 1, 2023  $4,717 
Loss on impairment of intangible asset   (1,042)
Amortization of intangible asset   (486)
      
Balance at December 31, 2023  $3,189 
Loss on impairment of intangible asset   (1,344)
Amortization of intangible asset   (366)
      
Balance at December 31, 2024  $1,479 
      
Loss on impairment of intangible asset   (115)
Amortization of intangible asset   (194)
      
Balance at December 31, 2025  $1,170 

 

NOTE 12:- TRADE PAYABLES

 

   December 31, 
   2025   2024 
Accrued expenses  $495   $608 
Open debts   288    208 
           
   $783   $816 

 

F-28

 

 

SCISPARC LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

USD in thousands (except share data)

 

NOTE 13:- OTHER PAYABLES

 

   December 31, 
   2025   2024 
Employees and payroll accruals  $85   $75 
Accrued vacation   175    130 
           
   $260   $205 

 

NOTE 14:- FINANCIAL INSTRUMENTS

 

  a. Classification of financial assets and financial liabilities:

 

The financial assets and financial liabilities in the consolidated statements of financial position are classified by groups of financial instruments pursuant to IFRS 9, “Financial Instruments” (“IFRS 9”):

 

   December 31, 
   2025   2024 
Financial assets:        
Cash, cash equivalents and restricted deposits  $4,611   $1,560 
Current maturities of long-term loan   451    
-
 
Other receivables   97    449 
Related parties   15    4,239 
           
Total financial assets at amortized cost   5,174    6,248 
           
Investments in financial assets at fair value   997    871 
           
Financial liabilities:          
           
Credit from others   85    75 
Loans   356    
-
 
Lease liability   10    48 
           
Total financial and lease liabilities  $451   $123 

 

F-29

 

 

SCISPARC LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

USD in thousands (except share data)

 

NOTE 14:- FINANCIAL INSTRUMENTS (CONT.)

 

  a. Classification of financial assets and financial liabilities: (Cont.)

 

The following table presents the Level 1-3 financial instruments as of December 31, 2025, and 2024:

 

   Carrying amount   Fair Value 
   December 31,   December 31, 2025 
   2025   Level 1   Level 2   Level 3 
Investments in short-term financial assets  $
-
   $
-
   $
-
   $
-
 
Investments in financial assets  $997   $997   $
-
   $
-
 
Current maturities of long-term loan (see note 8c)  $451   $
-
   $
-
   $451 

 

   Carrying amount   Fair Value 
   December 31,   December 31, 2024 
   2024   Level 1   Level 2   Level 3 
Investments in short-term financial assets  $517   $517   $
-
   $
-
 
Investments in financial assets  $354   $354   $
-
   $
-
 
Loans to a related party (see note 8c)  $4,224   $
-
   $
-
   $4,224 

 

Investments in short-term financial assets consist of an investment in Polyrizon Ltd. pre-funded warrants (see Note 24g).

 

Investments in financial assets consist of investments in Nexentis, AutoMax, Nexera (as defined in Note 18e) and Clearmind (refer to notes 7, 8b, 24d and 8a, respectively).

 

Management believes that the carrying amount of cash, short-term deposits, trade receivables, trade payables, and other current liabilities approximate their fair value due to the short-term maturities of these instruments.

 

For changes in the fair values of financial instruments measured at fair value through profit refer to Note 21.

 

  b. Financial risk factors:

 

The Company’s activities expose it to various financial risks such as market risks (foreign currency risk and interest risk), credit risk and liquidity risk. The Company’s comprehensive risk management plan focuses on activities that reduce to a minimum any possible adverse effects on the Company’s financial performance.

 

Risk management is performed by management in accordance with the policies approved by the Board. The Board establishes written principles for the overall risk management activities as well as specific policies with respect to certain exposures to risks such as exchange rate risk, credit risk and the investments of surplus funds.

 

  1. Market risks:

 

Foreign currency risk:

 

The Company is exposed to exchange rate risk resulting from the exposure to different currencies, mainly from transactions in NIS and CAD. Exchange rate risk arises from recognized liabilities that are denominated in a foreign currency other than the functional currency. The exchange rate risk arising from NIS and CAD balances are immaterial as the substantial amount of the monetary items is denominated in USD.

 

F-30

 

 

SCISPARC LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

USD in thousands (except share data)

 

NOTE 14:- FINANCIAL INSTRUMENTS (CONT.)

 

  b. Financial risk factors: (Cont.)

 

  2. Credit risks:

 

All cash and restricted deposits related to the Company are held in two banks in Israel which are considered financially solid.

 

  3. Liquidity risk:

 

The Company monitors the risk of a shortage of funds on a regular basis and acts to raise funds to satisfy its liabilities. As of December 31, 2025, the Company expects to settle all of its financial liabilities in less than one year.

 

The carrying amounts of cash and restricted deposits, and all other financial assets and liabilities approximate their fair value.

 

Below is an analysis of contractual maturities of financial liabilities, including estimated interest payments and the effect of discounting, as at December 31, 2025 and 2024:

 

   Carrying Amount   Contractual Cash flow   1 year   2-5 years 
December 31, 2025                
Accounts payable   783    783    783    
-
 
Other payables   270    270    270    - 
Related parties   726    726    504    222 
Current maturities of long-term loans   356    356    356    
-
 
Accrued legal contingency   340    340    340    
-
 
    2,475    2,475    2,253    222 

 

   Carrying Amount   Contractual Cash flow   1 year   2-5 years 
December 31, 2024                
Accounts payable   816    816    816    
-
 
Other payables   242    242    242    
-
 
Lease liability   9    9    
-
    9 
Accrued legal contingency   341    341    341    
-
 
    1,408    1,408    1,399    9 

 

The table below presents the change in the Company’s financial instruments as of December 31, 2025:

 

   Fair value measurements using input type 
   Level 1   Level 2   Level 3   Total 
Balance as of January 1, 2025   871    
-
    4,224    5,095 
Loan to related party             2,000    2,000 
Interest on loan             200    200 
Impairment of loan   
-
    
-
    (5,973)   (5,973)
Change in fair value   126    
-
    
-
    126 
Balance as of December 31, 2025   997    
-
    451    1,448 

 

F-31

 

 

SCISPARC LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

USD in thousands (except share data)

 

NOTE 15:- EMPLOYEE BENEFIT LIABILITIES

 

Employee benefits consist of short-term benefits and post-employment benefits.

 

Post-employment benefits:

 

According to the labor laws and the Israeli Severance Pay Law, 1963 (the “Severance Pay Law”), the Company is required to pay compensation to an employee upon dismissal or retirement or to make current contributions in defined contribution plans pursuant to Section 14 of the Severance Pay Law, as specified below. The Company’s obligation to pay such compensation is accounted for as a post-employment benefit. The computation of the Company’s employee benefit liability is made in accordance with a valid employment contract based on the employee’s salary and employment term which establish the entitlement to receive the compensation.

 

The post-employment benefits are normally financed by contributions classified as defined benefit plans or as defined contribution plans as detailed below.

 

Defined contribution plans:

 

The Severance Pay Law applies to a substantial part of the compensation payments, pursuant to which the fixed contributions paid by the Company into pension funds and/or policies of insurance companies release the Company from any additional liability to employees for whom said contributions were made. These contributions and contributions for compensation are accounted for as defined contribution plans.

 

   Year ended December 31, 
   2025   2024   2023 
Expenses in respect of defined contribution plans  $112   $106   $105 

 

NOTE 16:- TAXES ON INCOME

 

  a. Tax rates applicable to the Company:

 

The Israeli statutory corporate tax rate and real capital gains tax rate were 23% in 2025, 2024 and 2023. The combined U.S. federal and state tax rate was 28% in 2025, 2024 and 2023. The Canadian corporate tax rate was 27% in 2025, 2024 and 2023.

 

  b. Tax assessments:

 

The assessments of the Company are deemed final through the 2019 tax year.

 

  c. Carryforward tax losses and other temporary differences:

 

The Company has accumulated tax losses since its inception.

 

As of December 31, 2025, the Company’s net carryforward tax losses are estimated to be approximately $78,000, of which SNI’s losses amount to $1,300 and NeuroThera’s amount to $1,328.

 

F-32

 

 

SCISPARC LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

USD in thousands (except share data)

 

NOTE 17:- CONTINGENT LIABILITIES, COMMITMENTS, CLAIMS AND LIENS

 

  a. License Agreement with Dekel Pharmaceuticals Ltd.:

 

In May 2015, the Company entered into an exclusive, irrevocable, worldwide license agreement with Dekel for certain technology and one granted U.S. patent related to compositions and methods for treating inflammatory disorders (the “Dekel License Agreement”). The Dekel License Agreement became effective in August 2015.

 

On February 16, 2025, the Dekel License Agreement was terminated, as part of a settlement of a lawsuit filed against SciSparc’s former directors, effective as of February 5, 2024. In accordance with the settlement, SciSparc retained its exclusive global rights to its intellectual property portfolio, patents, know-how and technologies and was released from all alleged commitments, claims and royalties related or arising out of the Dekel License Agreement, including those related to claimed core technologies, and Dekel assumed full and exclusive ownership of the patent application for compositions and methods for treating inflammatory disorders and all such underlying intellectual property.

 

  b. License Agreement with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (“Yissum”):

 

On July 29, 2018, the Company entered into an exclusive, worldwide, sublicensable, royalty-bearing license with Yissum for a license to make commercial use of the licensed technology, in order to develop, obtain regulatory approvals, manufacture, market, distribute or sell products, all within the field and the territory only, as determined in the agreement (the “Yissum License Agreement”). According to the Yissum License Agreement, the Company shall pay Yissum royalties at the rates of future net sales, subject to the royalty reductions as described in the Yissum License Agreement. The Company is also obligated to pay sublicense fees out of the sublicense consideration. All rights, title and interest in and to the Yissum License Agreement shall vest solely in Yissum, and the Company shall hold and make use of the rights granted. All rights in the development results shall be solely owned by the Company, except to the extent that an employee of Yissum, including the researcher, is considered an inventor of a patentable invention arising from the development results, in which case such invention and all patent applications and/or patents claiming such invention shall be owned jointly by the Company and Yissum, as appropriate, and Yissum’s share in such joint patents shall be automatically included in the Yissum License Agreement.

 

  c. Agreement with Hannover Medical School:

 

On August 13, 2018, the Company entered into an agreement with Hannover Medical School to conduct a clinical study to evaluate the safety, tolerability and efficacy of daily oral SCI-110 in treating adults with Tourette syndrome, which agreement was subsequently updated on December 2, 2021, in an estimated amount of $1,385.

 

  d.

Agreement with Yale University:

 

On July 27, 2022, the Company entered into an agreement with Yale University to conduct a clinical investigation and laboratory services for a randomized, double-blind, placebo-controlled, cross over study to evaluate the safety, tolerability and efficacy of daily oral SCI-110 in treating adults with Tourette syndrome in treating approximately 10 Tourette syndrome subjects aged 18 to 65. The total estimated amount of the agreement is approximately $370.

 

F-33

 

 

SCISPARC LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

USD in thousands (except share data)

 

NOTE 17:- CONTINGENT LIABILITIES, COMMITMENTS, CLAIMS AND LIENS (CONT.)

 

  e. On May 2, 2023, Capital Point Ltd. (“Capital Point”) filed with the Tel Aviv-Jaffa District Court (the “Court”) a suit against the Company (the “Suit”).
     
    The Suit challenges a certain warrant issued by the Company to Capital Point (the “Capital Point Warrant”) to purchase ordinary shares of the Company in the amount of $340 (the “Warrant Shares”). The Capital Point Warrant was exercisable for 12 months from May 15, 2021, to May 15, 2022. The Suit claims that the Company unlawfully refused to accept the Capital Point Warrant exercise notice as of November 4, 2021.
     
    The Suit claims damages in the amount of NIS 10,000,000 (approximately $3.13 million), which accounts for, as of the date of the filing of the Suit, the agreed compensation according to Section 2(d)(i) of the Capital Point Warrant, an injunction order for the Company to issue the Warrant Shares to Capital Point, return of any unlawful profits received by the Company and punitive damages.
     
   

As of the Approval Date the Company believes it is unlikely that the outcome of the lawsuit exceeds the $340 thousand par value of the warrants.

 

  f.

Government grants:

 

The Company received research and development grants from the IIA. See also Note 2r. If no economic benefits are expected from the research activity, the royalty obligation is not recorded as a liability and instead is treated as a contingent liability in accordance with IAS 37.

 

During 2015-2017, the Company received IIA royalty-bearing grants totaling approximately $1,100 and as of December 31, 2025 there are no economic benefits that are expected in relation to these grants.  

 

NOTE 18:- EQUITY

 

  a. Composition of share capital:

 

   December 31, 2025   December 31, 2024 
   Authorized   Issued and
outstanding
   Authorized   Issued and
outstanding
 
   Number of shares 
Ordinary shares   75,000,000    365,444    75,000,000    57,293 

 

F-34

 

 

SCISPARC LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

USD in thousands (except share data)

 

NOTE 18:- EQUITY (CONT.)

 

  a. Composition of share capital: (Cont.)

 

Reverse Share Splits

 

On September 28, 2023, July 3, 2025 and February 5, 2026, the Company effected one-for-twenty six (1-for-26), one-for-twenty one (1-for-21) and one-for-nine (1-for-9) reverse splits, respectively.  

 

Consequently, all share and per share data included in these consolidated financial statements for all periods preceding the effective dates of the reverse share splits have been adjusted to reflect the reverse splits’ ratios in these consolidated financial statements for all periods presented.

 

  b. Changes in share capital:

 

Issued and outstanding share capital:

 

   Number of
ordinary
shares
 
     
Balance at January 1, 2024   3,739 
      
Issuance of share capital – in respect of exercise of October 2023 pre-funded warrants  (Note 18g)   19,457 
      
Shares issued to consultants (Note 19(a)(3))   3,419 
      
Issuance of share capital – in respect of January 2024 SEPA (Note 18(h))   30,678 
      
Balance at December 31, 2024   57,293 
      
Shares issued to consultants in respect of exercised restricted share units (“RSUs”) (Note 18e)   4,205 
      
Exercise of convertible debentures (Note 18i)   119,094 
      
Exercise of warrants (Note 18j)   40,172 
      
Issuance of shares in a registered direct offering (Note 18k)   143,617 
      
Shares issued to consultants (Note 19(a)(3))   1,059 
      
Rounding shares   4 
      
Balance at December 31, 2025   365,444 

 

F-35

 

 

SCISPARC LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

USD in thousands (except share data)

 

NOTE 18:- EQUITY (CONT.)

 

  c. Rights attached to shares:

 

Voting rights at the shareholders meeting, right to dividends, rights upon liquidation of the Company and right to nominate the directors in the Company.

 

  d. Capital management in the Company:

 

The Company’s capital management objectives are to preserve the Company’s ability to ensure business continuity thereby creating a return for the shareholders, investors and other interested parties. The Company is not under any minimal equity requirements nor is it required to attain a certain level of capital return.

 

  e. Additional issuances of ordinary shares:

 

On March 22, 2023, the Company issued 73 ordinary shares in respect of the stock purchase agreement entered into with Nexera Technologies Ltd. (“Nexera”) (formerly known as Jeffs’ Brands Ltd.) (see also Note 24d).

 

  f. August 2023 Financing Round

 

On August 14, 2023, the Company closed an underwritten public offering (the “2023 Public Offering”) of 1,124 ordinary shares, at a purchase price of $982.80 per ordinary share and pre-funded warrants to purchase up to 198 ordinary shares at a purchase price of $977.886 per pre-funded warrant, for aggregate gross proceeds of approximately $1,300, pursuant to an underwriting agreement between the Company and Aegis Capital Corp (“Aegis”), the underwriter in the 2023 Public Offering, dated August 10, 2023.

 

F-36

 

 

SCISPARC LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

USD in thousands (except share data)

 

NOTE 18:- EQUITY (CONT.)

 

  g. October 2023 Financing Round

 

On October 13, 2023, the Company announced the closing of a private placement with an institutional investor with gross cash proceeds to the Company of approximately $5,026, before deducting fees to the placement agent and other offering expenses payable by the Company.

 

In connection with the private placement, the Company issued an aggregate of 10,212 units, each unit consisting of two pre-funded warrants (the “Pre-Funded Warrants”). The Pre-Funded Warrants have an exercise price of $0.189, are immediately exercisable upon issuance and have a term of five years from the date of issuance.

 

During the year ended December 31, 2024, the Company issued 19,457 ordinary shares in respect of the exercise of 19,457 Pre-Funded Warrants.

 

  h. January 2024 Standby Equity Purchase Agreement

 

On January 21, 2024, the Company entered into a Standby Equity Purchase Agreement (“SEPA”), as amended on February 26, 2024, with YA II PN, LTD (“YA”), which provided for the sale of the Company’s ordinary shares in the amount of up to $20,000 (the “Advance Shares”). As of December 31, 2024, of the $20,000 eligible to be sold pursuant to the SEPA (the “Commitment Amount”), the Company has sold 30,385 ordinary shares for total proceeds of $6,255. The Advance Shares to be purchased or purchased by YA pursuant to the SEPA are for a share price of 97% of the market price, which is defined as the lowest daily volume weighted average price of the Company’s ordinary shares during the three consecutive trading days commencing on the trading day immediately following the delivery of an advance notice to YA.

 

In connection with the SEPA, the Company may request pre-paid advances of the Commitment Amount, in an amount of up to $5,000 (each a “Pre-Paid Advance”). Each Pre-Paid Advance will be evidenced by a promissory note (each a “Promissory Note”). Each Promissory Note will fully mature 24 months following its issuance and shall accrue interest on the outstanding principal balance thereon at a rate of 5% per annum, increasing to 18% per annum upon an Event of Default (as defined in the Promissory Note). Beginning 150 days after the issuance of a Promissory Note, the Company shall pay to YA a monthly installment payment of 10% of the original principal amount of the Promissory Note and accrued interest, payable in cash or by submitting an advance notice, where YA will offset the amount due to be paid to the Company under such notice against an equal amount of the monthly installment amount, at the Company’s option. If the Company elects to pay in cash, the installment amount shall also include a payment premium in the amount of 5% of the principal amount of the installment payment. The Promissory Note contains the Company’s customary representations and warranties and events of default.

  

In addition, pursuant to the SEPA, the Company issued to YA an aggregate of 293 of its ordinary shares, or the Commitment Shares, in satisfaction of payment of the commitment fee of $200.

 

F-37

 

 

SCISPARC LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

USD in thousands (except share data)

 

NOTE 18:- EQUITY (CONT.)

 

  i. August 2025 convertible debenture exercises
     
    On February 25, 2025, the Company entered into securities purchase agreements (the “Securities Purchase Agreements”) with certain investors, pursuant to which the Company sold convertible debentures (the “Debentures”) in the aggregate principal amount of $4,200 (the “Subscription Amount”), which are convertible into the Company’s ordinary shares (as converted, the “Conversion Shares”), at a purchase price equal to 95% of the Subscription Amount. The issuance and sale of the Debentures was subject to certain conditions and limitations.
     
    In August 2025, certain investors under the Securities Purchase Agreements, submitted to the Company conversion notices to convert outstanding principal and accrued interest of certain Debentures, pursuant to which the Company issued an aggregate of 119,094 ordinary shares.
     
   

As a result of issuance and conversion of the Debentures, the Company recorded net finance expense of $170 in the consolidated statements of comprehensive loss for the year ended December 31, 2025.

 

  j. September 2025 Warrant exercises
     
    At the closing of the Securities Purchase Agreements (see note 18i above), the Company issued to the investors 40,172 warrants which are exercisable into a number of ordinary shares equal to the Subscription Amount applicable to the investors divided by a price equal to 130% of the volume weighted average price of the ordinary shares immediately prior to the closing date, or $104.5548 per warrant.
     
    On September 26, 2025, the Company entered into inducement offer letter agreements (the “Inducement Letters”) with holders (the “Holders”) of certain of the existing warrants to purchase in the aggregate up to 40,172 of the ordinary shares, issued on February 25, 2025, at an exercise price of $104.5548 per ordinary share (the “Existing Warrants”). Pursuant to the Inducement Letters, the Holders agreed to exercise for cash all of their Existing Warrants at a reduced exercise price of $27.90 per ordinary share. The Company received aggregate gross proceeds of approximately $1,121 from the exercise of the Existing Warrants by the Holders.
     
   

As a result of issuance and exercise of the Existing Warrants, which were measured at fair value from the date of issuance until exercise, the Company recorded net finance income of $1,750 in the consolidated statements of comprehensive loss for the year ended December 31, 2025.

 

  k. November 2025 Registered Direct Offering
     
    On November 27, 2025, the Company entered into a securities purchase agreement with certain institutional and accredited investors, providing for the issuance of an aggregate of 143,617 ordinary shares, at a purchase price of $15.75. The registered direct offering resulted in gross proceeds in the amount of $2,262.

 

  l. Warrants
     
    The following table summarizes information of outstanding warrants as of December 31, 2025:

 

Warrants  Warrant Term  Exercise Price  Exercisable 
               
March 2021 Series A Warrants  March 1, 2026  USD   34,743    233 
March 2021 Series B Warrants  March 1, 2026  USD   52,088    117 
May 2022 Warrants  May 27, 2027  USD   12,924    1,443 
               1,793 

 

F-38

 

 

SCISPARC LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

USD in thousands (except share data)

 

NOTE 19:- SHARE-BASED PAYMENT TRANSACTIONS

 

  a. The cost of share-based payment recognized in the consolidated financial statements:

 

The expenses due to share-based compensation for the years ended December 31, 2025, 2024 and 2023, recognized in the consolidated financial statements in respect of the share option plan of the Company are shown in the following table, detailed by expense classification:

 

   Year ended December 31, 
   2025   2024   2023 
Research and development expenses  $85   $45   $34 
General and administrative expenses   1,103    524    162 
                
   $1,188   $569   $196 

 

  1. The 2015 ESOP and 2023 Plan:

 

On December 28, 2023, the Board adopted the 2023 Share Incentive Plan (the “2023 Plan”).

 

The Company no longer grants any awards under the 2015 ESOP as it was superseded by the 2023 Plan, although previously granted awards under the 2015 ESOP remain outstanding and subject to the 2015 ESOP. Under the 2023 Plan, the Company may grant its employees and other service providers equity-based incentive awards (“Share Options”).

 

On December 28, 2023, the Board approved to reserve for issuance under the 2023 Plan 5,291 ordinary shares.

 

  2. During the year ended December 31, 2025, share-based compensation in respect of Share Options of $0 was charged to the consolidated statements of comprehensive loss ($7 and $103 for the years ended December 31, 2024 and 2023, respectively).

 

  3. During the years ended December 31, 2025 and 2024, the Company issued consultants 1,059 and 3,419 ordinary shares, respectively, for services rendered. The shares were granted at a discount rate of 25% to the share price quoted on the date of each grant. The total fair value of the ordinary shares granted to consultants in the years ended December 31, 2025 and 2024 was $106 and $105, respectively.

 

F-39

 

 

SCISPARC LTD. AND ITS SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS 
USD in thousands (except share data)

 

NOTE 19:- SHARE-BASED PAYMENT TRANSACTIONS (CONT.)

 

  b. Movement during the year:

 

  1. The following table lists the number of Share Options, the weighted average exercise prices of Share Options and changes in directors (and former directors), officers, employees and consultants Share Options during the years ended on December 31, 2025, and 2024:

 

   Number of
Share
Options
   Weighted
average
exercise
price
 
       USD 
2025:        
Share Options outstanding at the beginning of the year   36    53,940.24 
           
Share Options outstanding at the end of the year   36    53,940.24 
           
Share Options exercisable at the end of the year   36    53,940.24 
           
2024:          
Share Options outstanding at the beginning of the year   37    31,426.92 
           
Share Options outstanding at the end of the year   36    53,940.24 
           
Share Options exercisable at the end of the year   36    53,940.24 

  

  2. The weighted average remaining contractual life of the Share Options outstanding was 2.04 years and 2.99 years as of December 31, 2025 and 2024, respectively.

 

  3. The range of exercise prices of Share Options outstanding at the end of the year was $31,941 - $2,063,880 (inclusive) as of December 31, 2025 and 2024, respectively.

 

F-40

 

 

SCISPARC LTD. AND ITS SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
USD in thousands (except share data)

 

NOTE 19:- SHARE-BASED PAYMENT TRANSACTIONS (CONT.)

 

  c. Restricted Share Units:

 

RSU transactions for the years ended December 31, 2025, and 2024 are as follows:

 

   Number 
Balance, January 1, 2024   
-
 
RSUs granted   5,628 

Vesting of RSUs

   
-
 
Balance, December 31, 2024   5,628 
      

Vesting of RSUs

   (4,205)
RSUs granted   56,111 
Balance, December 31, 2025   57,534 

 

There were no RSUs that are vested and not issued as of December 31, 2025. For the year ended December 31, 2025, share-based compensation in respect of RSUs of $867 was charged to the Consolidated Statements of Comprehensive Loss (and $456 for the year ended December 31, 2024).

 

NOTE 20:- COST OF REVENUES

 

The following table discloses the breakdown of our cost of revenues for the periods set forth below:

 

   Year ended December 31, 
   2025   2024   2023 
             
Purchased goods  $225   $798   $672 
Freight   
-
    2    11 
                
    225    800    683 

 

F-41

 

 

SCISPARC LTD. AND ITS SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
USD in thousands (except share data)

 

NOTE 21:- ADDITIONAL INFORMATION TO THE ITEMS OF PROFIT OR LOSS

 

     Year ended December 31,     
     2025   2024   2023 
a. Research and development expenses:               
  Wages and related expenses  $329   $390   $392 
  Share-based payment   85    45    34 
  Regulatory, professional and other expenses   980    681    719 
  Research and preclinical studies   364    211    101 
  Clinical studies   266    276    254 
  Chemistry and formulations   73    104    141 
                  
      2,097    1,707    1,641 
                  
b. Sales and marketing expenses:               
  Advertising  $155   $367   $576 
  Amazon fees   331    495    1,042 
  Amortization   194    366    486 
  Storage and shipping   112    167    145 
  Management fees   120    120    235 
                  
      912    1,515    2,484 
c. General and administrative expenses:               
  Wages and related expenses   458    507    415 
  Share-based payment   1,103    419    68 
  Professional and directors’ fees   2,823    3,009    2,594 
  Deemed issuance listing expenses   1,410    
-
    
-
 
  Business development expenses   89    108    86 
  Regulatory expenses   222    158    202 
  Office maintenance, rent and other expenses   152    128    110 
  Investor relations and business expenses   114    197    369 
                  
      6,371    4,526    3,844 
d. Other income, net:               
  Loss from sale of property and equipment   
-
    17    
-
 
  Gain on settlement of legal dispute   (464)   
-
    
-
 
  Other income   (26)   
-
    
-
 
  Gain on sale of patent license, net (net of Polyrizon Ltd. holdings sold) (See also Note 24g)   
-
    (1,287)   
-
 
      (490)   (1,270)   
-
 
                  
e. Finance income:               
  Net change in fair value of financial liabilities designated at fair value through profit or loss   (1)   (191)   (2,205)
  Finance income due to cancellation of warrant liability   (1,568)   
-
    
-
 
  Finance income due to revaluation of convertible debentures   (422)   
-
    
-
 
  Interest from loans to related parties and deposits   (207)   (421)   
-
 
  Exchange rate differences   (80)   
-
    (14)
                  
      (2,278)   (612)   (2,219)
f. Finance expenses:               
  Impairment of loan (see note 8c)   5,973    
-
    
-
 
  Issuance expenses   410    
-
    
-
 
  Exchange rate differences   14    18    
-
 
  Losses from remeasurement of investment in financial assets   1,791    305    1,046 
  Finance expense in respect of leases   5    8    9 
  Finance expenses from interest and commissions   6    22    
-
 
                  
     $8,199   $353   $1,055 

 

F-42

 

 

SCISPARC LTD. AND ITS SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
USD in thousands (except share data)

 

NOTE 22:- LOSS PER SHARE

 

  a. Details of the number of shares and loss used in the computation of loss per share:

 

   Year ended December 31, 
   2025   2024   2023 
Amounts used in the computation of basic and diluted loss  Weighted
number of
shares
   Loss   Weighted
number of
shares
   Loss   Weighted
number of
shares
   Loss 
       USD       USD       USD 
Continuing operations:                        
                               
Basic loss per share   124,185    (12,179)   30,820    (6,284)   2,157    (5,122)
                               
Effect of potential dilutive ordinary shares   
-
    
-
    
-
    
-
    
-
    
-
 
                               
Basic and diluted loss per share   124,185    (12,179)   30,820    (6,284)   2,157    (5,122)

 

  b. The computation of diluted loss per share did not include the following dilutive potential ordinary shares since their inclusion would decrease the loss per share (anti-dilutive effect):

 

  1. 36 Share Options to employees, officers, directors and consultants;

 

  2. 1,793 non-marketable warrants to investors; and

 

  3. 57,534 RSUs granted to officers, directors and consultants.

 

F-43

 

 

SCISPARC LTD. AND ITS SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
USD in thousands (except share data)

 

NOTE 23:- OPERATING SEGMENTS

 

The Company applies the principles of IFRS 8, “Operating Segments (“IFRS 8”), regarding operating segments. The segment reporting is based on internal management reports of the Company’s management, which are regularly reviewed by the Chief Operating Decision Maker (“CODM”) to make decisions about resources to be allocated and assess performance. According to the principles of IFRS 8, the Company’s management determined that it has two reportable segments – (1) development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the Company’s operation); and (2) online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.

 

Segment performance (segment income (loss)) is evaluated based on operating income (loss) of each segment in the consolidated financial statements. The segment results reported to the CODM include items that are allocated directly to the segments and items that can be allocated on a reasonable basis.

 

The review of the CODM is carried out according to the results of the segment’s performance. His review does not include certain expenses that are not related specifically to the activity of each of the segments. Those expenses are presented as reconciliation between segments operating results to total operating results in financial statements.

 

The Group’s CODM is the CEO of the Company.

 

   Year ended December 31, 2025 
   Drug
Development
   Online
Sales
   Total 
Revenues            
External  $
-
   $856   $856 
Total   
-
    856    856 
                
Cost of revenues   
-
    225    225 
Research and development expenses   2,097    
-
    2,097 
Sales and marketing   
-
    912    912 
Impairment of intangible assets   
-
    115    115 
General and administrative expenses   6,279    92    6,371 
Other income, net   (490)   
-
    (490)
                
Segment loss   7,886    488    8,374 
Company’s share of losses of company accounted for at equity, net             500 
Gain from sale of an associate             (2,231)
Finance expense, net             5,921 
                
Loss             12,564 

 

F-44

 

 

SCISPARC LTD. AND ITS SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
USD in thousands (except share data)

 

NOTE 23:- OPERATING SEGMENTS (CONT.)

 

   Year ended December 31, 2024 
   Drug
Development
   Online
Sales
   Total 
Revenues            
External  $
-
   $1,306   $1,306 
Total   
-
    1,306    1,306 
                
Cost of revenues   
-
    800    800 
Research and development expenses   1,707    
-
    1,707 
Sales and marketing   
-
    1,515    1,515 
Impairment of intangible assets   
-
    1,344    1,344 
General and administrative expenses   4,436    90    4,526 
Other income, net   (1,270)   
-
    (1,270)
                
Segment loss (gain)   4,873    2,443    7,316 
                
Equity losses from the investment in MitoCareX             429 
Finance expense (income), net             (259)
Tax income             (14)
                
 Loss             7,472 

 

   Year ended December 31, 2023 
   Drug
Development
   Online
Sales
   Total 
Revenues            
External  $
-
   $2,879   $2,879 
Total   
-
    2,879    2,879 
                
Cost of revenues   
-
    683    683 
Research and development expenses   1,641    
-
    1,641 
Sales and marketing   
-
    2,484    2,484 
Impairment of intangible assets   
-
    1,042    1,042 
General and administrative expenses   3,718    126    3,844 
Other income, net   
-
    
-
    
-
 
                
Segment loss (gain)   5,359    1,456    6,815 
                
Company’s share of losses of company accounted for at equity, net             210 
Finance expense (income), net             (1,164)
Tax expense             22 
                
Loss             5,883 

 

F-45

 

 

SCISPARC LTD. AND ITS SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
USD in thousands (except share data)

 

NOTE 23:- OPERATING SEGMENTS (CONT.)

 

Drug Development Segment

 

For the year ended December 31, 2024, the Company recognized other income in the amount of $1,288 as a result of a sale of an intangible asset.

 

Online Sales Segment

 

For the years ended December 31, 2023, 2024 and 2025, the Brand recorded significant losses. As of December 31, 2025, the Company has determined there are signs of decline in the value of the Brand and recognized a loss as a result of impairment to its intangible asset of $115 (as of December 31, 2024 - $1,344, as of December 31, 2023 - $1,042).

 

   As of December 31, 2025 
   Drug
Development
   Online
Sales
   Total 
             
Segment assets  $6,224   $1,398   $7,622 
Segment liabilities  $2,213   $262   $2,475 

 

   As of December 31, 2024 
   Drug
Development
   Online
Sales
   Total 
             
Segment assets  $8,407   $1,764   $10,171 
Segment liabilities  $1,194   $226   $1,420 

 

F-46

 

 

SCISPARC LTD. AND ITS SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
USD in thousands (except share data)

 

NOTE 24:- TRANSACTIONS AND BALANCES WITH RELATED PARTIES

 

  a. Balances with related parties:

 

   December 31, 2025   December 31, 2024 
   Key
management
personnel
   Other
related
parties
   Key
management
personnel
   Other
related
parties
 
AutoMax bridge loans (see note 8c)  $
-
   $
-
   $
-
   $4,224 
Other current assets  $
-
   $15   $
-
   $15 
Current liabilities (see note 24e)  $123   $381   $55   $245 
Non-current liabilities  $
-
   $222   $
-
   $
-
 

 

  b. Transactions with related parties (not including amounts described in Note 24c):

 

   Year ended December 31, 
   2025   2024   2023 
Research and development expenses  $216   $63   $40 
Sale of non-controlling interest in subsidiary  $
-
   $
-
   $2,985 

 

  c. Benefits to key management personnel (including directors):

 

   Year ended December 31, 
   2025   2024   2023 
Short-term benefits  $1,142   $765   $1,204 
                
Management fees (see also note 24d)  $120   $120   $220 
                
Cost of share-based payment  $302   $157   $84 

 

  d. Pursuant to the purchase of the Wellution brand (refer to note 11), Nexera and SciSparc U.S. entered into a consulting agreement, pursuant to which Nexera provides management services to SciSparc US for the Wellution brand for a monthly fee of $20 and Nexera received a one-time signing bonus in the amount of $51. The consulting agreement is for an undefined period of time and may be terminated by either party with 30 days advance notice. On November 2023 the monthly fee was reduced to $10. For the years ended December 31, 2025 and 2024, the Company has recorded management services expenses in the amount of $120.

 

F-47

 

 

SCISPARC LTD. AND ITS SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
USD in thousands (except share data)

 

NOTE 24:- TRANSACTIONS AND BALANCES WITH RELATED PARTIES (CONT.)

 

   

In addition, during 2023 the Company and Nexera engaged in a mutual share exchange in the amount of $288 of ordinary shares from each of the Company and Nexera. Accordingly, the Company acquired 35,345 ordinary shares of Nexera and Nexera acquired 660 ordinary shares of the Company having an aggregate value of $288 As of December 31, 2025, the listed share price of Nexera on Nasdaq was $0.822, and the Company has recorded a loss in its consolidated statements of comprehensive loss of $89 on its investment (and $17 for the year ended December 31, 2024).

     
    Mr. Oz Adler, the Company’s Chief Executive Officer and Chief Financial Officer, is the chairman of the board of directors of Nexera.
     
  e. On March 7, 2022, the Company entered into the Cooperation Agreement with Clearmind, a company in which Dr. Adi Zuloff-Shani, the Company’s Chief Technologies Officer, Mr. Weiss, the Company’s President, and Mr. Adler, the Company’s Chief Executive Officer and Chief Financial Officer serve as officers and directors (the “Cooperation Agreement”).   For the years ended December 31, 2025 and 2024, the Company recognized expenses in respect of the Cooperation Agreement in the amount of $216 and $63, respectively. As of December 31, 2025, amounts owed to Clearmind in respect of the Cooperation Agreement amount to $381.
     
    On November 17, 2022, the Company invested $1.5 million in Clearmind in connection with its initial public offering on the Nasdaq Capital Market, in exchange for 192 common shares of Clearmind, representing 9.33% of the outstanding share capital of Clearmind (see also Note 8).

 

  f.

Mr. Amitai Weiss, one of the Company’s directors, was formerly chairman of the board of directors of AutoMax (see Note 8b).

 

  g.

On August 13, 2024, the Company entered into the license agreement (the “License Agreement”) of the out-licensing of its SCI-160 program (the “Assets”), with Polyrizon Ltd. (the “Licensee” or “Polyrizon”). According to the License Agreement, the Company granted the Licensee a royalty-bearing, exclusive, sub-licensable right and license to the Assets (the “License”). In consideration for the License, the Company received and will receive certain shares of the Licensee, reflecting an issue price of $805, and royalties from sales related to and income generated from the Assets. Further, the Licensee will pay the Company pre-determined fees upon the completion of certain development milestones relating to the Assets.

 

Pursuant to the terms of the License Agreement, the Company is entitled to up to $3,320 based on the achievement of certain milestones, including (i) $50 upon a successful preclinical safety test, (ii) $100 upon first patient enrolled in phase I clinical trial, (iii) $120 upon first patient enrolled in Phase 2a clinical trial, (iv) $150 upon first patient enrolled in Phase 2b clinical trial, (v) $500 upon first patient enrolled in Phase 3 clinical trials, (vi) $800 upon approval by the U.S. Food and Drug Administration, (vii) $800 upon approval by an EU regulatory body, and (viii) $800 upon regulatory approval in any additional jurisdiction. Additionally, the Company is eligible to receive royalties, on a country-by-country and product-by-product basis, at a rate of 5%, on aggregate net sales of a product that comprises, contains and/or incorporates and/or is based on the Licensed Patent Rights, or a Licensed Product (as these are defined in the License Agreement), and sublicense income that we may receive until the longer of (i) fifteen years from the date of the first sale of a Licensed Product (on a country-by-country basis), and (ii) the last to expire valid claim of any licensed patents with respect to a Licensed Product in such country.

 

On October 31, 2024, following an initial public offering of the Licensee, the Company received 684,931 units, of which (i) 320,000 units, with each unit consisting of one ordinary share of the Licensee and three warrants, each to purchase one additional ordinary share of the Licensee at a purchase price of $4.38 (960,000 warrants in total); and (ii) 364,931 units consisting of one pre-funded warrant to purchase one ordinary share of the Licensee, and three warrants, each to purchase one additional ordinary share of the Licensee at a purchase price of $4.38 (1,094,793 warrants in total). Altogether, the Company received 320,000 ordinary shares, 364,931 pre-funded warrants to purchase one ordinary share of the Licensee, and 2,054,793 warrants to purchase one additional ordinary share of the Licensee at a purchase price of $4.38.

 

On December 30, 2024, pursuant to a share transfer agreement, the Company sold all of the Licensee ordinary shares and pre-funded warrants held by it to a third party, as well as an aggregate of 1,541,096 Licensee common warrants to third parties, for aggregate consideration of $771. In addition, in consideration for the License, the Company will receive royalties from sales related to the Assets and income generated from it.

 

On April 1, 2025, the Company entered into a securities purchase agreement with Polyrizon, pursuant to which the Company participated in a private placement of Polyrizon and invested $100 (out of an aggregate investment of approximately $17 million), in exchange for ordinary shares and Series A warrants to purchase ordinary shares, of Polyrizon. In addition, the Company entered into an exchange agreement with Polyrizon, pursuant to which the Company exchanged existing ordinary share warrants of Polyrizon held the Company for Series A warrants to purchase ordinary shares of Polyrizon.

 

As of December 31, 2025, the Company holds 88 ordinary shares of the Licensee. The value of the ordinary shares on December 31, 2025, is $1.

 

Mr. Oz Adler, the Company’s Chief Executive Officer, is Chairman of the board of directors of Polyrizon.

 

F-48

 

 

SCISPARC LTD. AND ITS SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
USD in thousands (except share data)

 

NOTE 25:-

SIGNIFICANT EVENTS DURING THE REPORTING PERIOD

 

Transaction with NeuroThera Labs

 

On October 9, 2025, the Company entered into an asset and share purchase agreement (the “Miza Agreement”) with Miza III Ventures Inc. (TSXV: MIZA.P)(“Miza”), pursuant to which, on the terms and subject to the conditions of the Miza Agreement, the Company received a controlling interest in Miza, and transferred to Miza its clinical-stage pharmaceutical portfolio and equity stake of approximately 50.9% in SNI (the “Transaction”). In the financial statements of Miza, the Miza Agreement was accounted for as a reverse acquisition where SNI was identified as the accounting acquirer.

 

As of December 31, 2025, the Company held 75% of Miza issued and outstanding share capital. 

 

The Transaction closed on October 22, 2025, and pursuant to the Miza Agreement, at the closing thereof (the “Closing”) the Company transferred to Miza 59 ordinary shares, or approximately 50.9% of the equity, of SNI, the intellectual property rights in SciSparc’s clinical-stage pharmaceutical portfolio, and the contracts, permits, pre-paid deposits, books and records, business and technical information, and all other rights, properties and assets necessary to the operation thereto, in consideration for 63,300,000 common shares of Miza, at a deemed price per share of CAD 0.25 (“Miza Common Shares”), 4,000,000 common share purchase warrants exercisable to acquire one Miza Common Share for each warrant at an exercise price of CAD 0.25 for a period of five years from the date of issuance thereof (the “Warrants”), 3,000,000 common shares to finders, with an aggregate fair value of $321 and up to 48,000,000 Miza Common Shares (the “Contingent Rights Shares”) contingent upon the achievement of certain pre-determined milestones (the “Milestones”), representing a post-closing equity interest in Miza of 75% (or up to approximately 84% in the event of the full achievement of the Milestones.

 

Pursuant to the Miza Agreement, upon the achievement of the Milestones, the Contingent Right Shares will be issued to the Company as follows: (i) 16,000,000 Miza Common Shares will be issued upon the completion of a transaction resulting in the listing of Miza’s securities on either the New York Stock Exchange or the Nasdaq Stock Market LLC (each, a “U.S. Exchange”), or another transaction resulting in the issuance of shares listed on a U.S. Exchange to shareholders of Miza in exchange for their Miza Common Shares (in each case, an “Uplisting Transaction”), if such Uplisting Transaction is completed within twenty-four months from the date of Closing (the “Closing Date”); (ii) 16,000,000 Miza Common Shares will be issued upon the successful raising by Miza, within forty-eight months of the Closing Date in equity and/or debt financing, of an aggregate of US$10 million or more; and (iii) 16,000,000 Miza Common Shares will be issued upon Miza completing a clinical trial within forty-eight months of the Closing Date.

 

Upon Closing, two parties have provided Miza non-convertible loans in the amount of $175 each which mature on November 22, 2026 and bear interest at the simple rate of 7% per annum.

 

The financial statements of Miza are consolidated in these financial statements from the Closing Date, and the Miza Agreement was accounted for as deemed issuance of shares by a subsidiary. Following the Closing, Miza changed its name to “NeuroThera Labs Inc.” and is expected to be active in both the pharmaceutical and supplemental sectors. In the financial statements of Miza, the Miza Agreement was accounted for as a reverse acquisition where SNI was identified as the accounting acquirer. Additionally, Miza did not meet the definition of a business in IFRS 3, “Business Combinations.” Accordingly, in the consolidated financial statements of the Company the agreement was accounted for as deemed issuance of 18,600,000 common shares by a subsidiary, representing the shares deemed to have been issued to the non-controlling interests by the subsidiary, and as an equity-settled share-based payment transaction by a subsidiary for the provision of a stock exchange listing and related services in accordance with IFRS 2, “Share-based Payment.”

 

The deemed issuance listing expense related to the Transaction has been recorded in profit or loss and measured as the excess of fair value of  the 18,600,000 common shares deemed issued by Neurothera Labs Inc. over the fair value of Neurothera’s identifiable net assets acquired. The fair value of such common shares was determined based on their quoted price as of the date of completion of the Transaction.

 

The 3,000,000 common shares issued by the subsidiary to finders were recorded as share-based compensation expense in accordance with IFRS 2, “Share-based Payment,” in an amount of $321, determined based on the quoted price of the common shares as of the date of completion of the Transaction.

 

For further information regarding the assets and liabilities received as consideration for deemed issuance of shares, see appendix (b) to the consolidated statements of cash flows.

 

In addition, on October 23, 2025, the Company loaned CAD 1 million (approximately US$716 thousand) in cash to Miza pursuant to an unsecured convertible note, which shall mature on the two-year anniversary of the date of the issuance thereof (the “Maturity Date”) and shall bear interest at the simple rate of 7% per annum. On the Maturity Date, the outstanding principal and accrued but unpaid interest under the convertible note shall be convertible into Miza Common Shares, at the sole election of the holder, at a price of CAD 0.25 per share and up to a maximum of 4,000,000 Miza Common Shares (the “Share Cap”), subject to customary anti-dilution adjustments. Upon conversion of the convertible note, for any principal amount or accrued interest not converted into shares due to being in excess of the Share Cap or rounding, Miza will pay the holder of the convertible note a cash amount of such outstanding balance.This convertible note is eliminated in consolidation.

 

F-49

 

 

SCISPARC LTD. AND ITS SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
USD in thousands (except share data)

 

NOTE 26:- EVENTS AFTER THE REPORTING DATE

 

  The Company has evaluated subsequent events from December 31, 2025 through April 29, 2026, the date of approval of these consolidated financial statements by the board of directors.

 

  a.

On January 26, 2026, the Company closed acquisition of the complete portfolio of patents, trademarks, know-how, brand names and related intellectual property rights, including unregistered intellectual property rights, owned by Xylo Technologies Ltd. (“Xylo”) for pre-funded warrants to purchase 113,043 ordinary shares, at an exercise price of $0.009 per share to Xylo.

 

  b.

On January 13, 2026, the Company entered into a securities purchase agreement with certain institutional and accredited investors, providing for the issuance of an aggregate of 766,170 ordinary shares, at a purchase price of $1.00 per share. The offering resulted in gross proceeds of approximately $766,170. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes, as may be determined by the Company’s board of directors.

 

  c.

On February 12, 2026, the Company entered into a securities purchase agreement (the “SPA”) with an institutional investor (the “February 2026 Holder”). Pursuant to the SPA, the Company may issue and sell, from time to time, convertible promissory notes (the “February 2026 Notes”), in the aggregate principal amount of up to $10,000 (the “February 2026 Subscription Amount”). Upon the signing of the SPA, on February 12, 2026 (the “Initial Closing”), the Company issued to the February 2026 Holder a February 2026 Note in the principal amount of $2,000 for a purchase price of $1,800 (the “Initial Note”). Pursuant to a side letter entered into by the Company and the February 2026 Holder on February 12, 2026, the Company agreed that the February 2026 Holder deliver the purchase price for the Initial Note upon the filing of the Registration Statement (as described below) with the SEC. The Company intends to use the net proceeds from the sale of the February 2026 Notes and any additional net proceeds from the exercise of the Warrants (see below), to the extent exercised in cash, for working capital and general corporate purposes.  

 

Subject to the conditions in the SPA, beginning on April, 1, 2026, the Company may request, at its sole discretion, that the Holder purchase additional February 2026 Notes, each in the principal amount of up to $1,800, with a purchase price payable in cash and equal to 90% of such principal amount, during each subsequent three-month period. Notwithstanding the foregoing, if at any time after the Initial Closing, the daily trading volume of the Company’s ordinary shares is at least 150% of the amount of ordinary shares then outstanding, then the Company may request, at its sole discretion, that the February 2026 Holder purchase additional February 2026 Notes for a purchase price payable in cash equal to 90% of the principal amount, provided that the aggregate principal amount of all notes purchased pursuant to the SPA shall not exceed the February 2026 Subscription Amount.

 

In addition, under the terms and conditions of the SPA, concurrently with the issuance of each note, the Company shall issue to the Holder, for no additional consideration, an accompanying warrant to purchase the ordinary shares, representing a warrant coverage of 100% of the maximum number of ordinary shares issuable upon conversion of each such February 2026 Note (calculated based on the lower of (i) the closing price of the ordinary share on the Nasdaq Capital Market on the last trading day immediately prior to the date of issuance of such February 2026 Note and (ii) 88% of the lowest daily volume weighted average price during the 20 consecutive trading days immediately preceding the applicable date of conversion).  

 

Thus, at the Initial Closing, the Company issued to the February 2026 Holder a warrant to purchase up to 405,728 ordinary shares (the “Initial Warrant”). The Initial Warrant is exercisable upon issuance at an exercise price of $4.9293 and has a term of 3 years from the Issuance Date, or February 12, 2029.  

     
  d. On February 5, 2026, the Company announced that it intends to effect the Fifth Reverse Share Split of the Company’s issued and outstanding ordinary shares, effective on March 4, 2026. Consequently, all share numbers, share prices, and exercise prices have been retroactively adjusted in these consolidated financial statements for all periods presented. The Fifth Reverse Share Split was approved by the Company’s shareholders at the Company’s annual general meeting of shareholders held on June 26, 2025, to be effected at the board of directors’ discretion within the approved parameters.  

 

F-50

 

 

SCISPARC LTD. AND ITS SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
USD in thousands (except share data)

 

NOTE 26:- EVENTS AFTER THE REPORTING DATE (CONT.)

 

  e.

On February 28, 2026, a joint military operation (the “Operation”) commenced by the United States and Israel involving attacks in Iran. In response, Iran launched ballistic missiles and unmanned aerial vehicles toward Israel and certain states in the Persian Gulf region. These events have resulted in civilian casualties and property damage in Israel. Additionally, Hezbollah, a terrorist organization in Lebanon, joined the attacks against Israel and Israel has started military operations in Lebanon.

 

Following the commencement of the Operation, Israel’s Home Front Command announced a “special home front situation” and updated safety guidelines that include, among other measures, restrictions on passenger flights, limitations on gatherings, broad reserve recruitment, and temporary closure of certain businesses, which has contributed to a partial reduction in economic activity.  

     
    Subject to the continuation and/or escalation of the Operation, and given its adverse impact on economic conditions in Israel, management expects the Operation to have a negative effect on the Company. Because this is an ongoing event and there is uncertainty regarding its duration, nature, and scope, management is unable to reasonably estimate the extent of the impact at this time.  
     
  f.

On March 10, 2026, the Company announced that NeuroThera, in which the Company holds a controlling interest of approximately 75%, has entered into a definitive share purchase agreement (the “CliniQ SPA”), between NeuroThera, CliniQuantum Ltd. (“CliniQ”) and certain selling shareholders to acquire approximately 54.01% of the issued and outstanding ordinary shares of CliniQ (the “CliniQ Shares”) on a fully diluted basis immediately prior to the closing of the transaction (the “CliniQ Transaction”). CliniQ is a quantum technology company holding patents from Ramot, which is Tel Aviv University’s tech transfer company, in the field of quantum simulation and quantum Monte Claro.

 

Under the CliniQ SPA, NeuroThera will acquire 56,375 CliniQ Shares (the “Purchased Shares”), representing approximately 54.01% of the issued and outstanding ordinary shares of CliniQ from certain shareholders of CliniQ (collectively, the “Selling Shareholders”).  

 

In consideration for the Purchased Shares, NeuroThera will issue an aggregate of 56,600,000 common shares (the “Consideration Shares”) to the Selling Shareholders, representing an aggregate value of approximately $9,460 based on the volume weighted average trading price of the NeuroThera’s common shares on the TSXV for the 20 trading days immediately preceding the date of the determination.

 

In addition to the Consideration Shares, the Selling Shareholders may be entitled to receive earn-out payments of up to $2,500 in the aggregate (the “Earn-Out Payments”), payable in cash and/or common shares of NeuroThera at the sole discretion of NeuroThera, contingent upon the achievement of the certain milestones, including $500 for each of the first three patent applications filed by CliniQ with the United States Patent and Trademark Office or the European Patent Office, up to a maximum of $1,500 in the aggregate filed during the Earn-Out Period (as defined below); and an amount equal to 7.0% of any fundraising proceeds raised by NeuroThera, up to a maximum of $1,000 in the aggregate. The Earn-Out Payments, if any, are payable during the three-year period following the closing of the Transaction (the “Earn-Out Period”).  

 

Closing of the Transaction is expected to occur within 30 days following the submission of the application for the Israeli tax ruling to the Israeli Tax Authority, subject to satisfaction or waiver of all closing conditions. The closing of the Transaction is anticipated to be on or about May 15, 2026, unless otherwise agreed by the parties in writing.  

 

F-51

 

0001611746 true FY 0001611746 2025-01-01 2025-12-31 0001611746 dei:BusinessContactMember 2025-01-01 2025-12-31 0001611746 2025-12-31 0001611746 2024-12-31 0001611746 2024-01-01 2024-12-31 0001611746 2023-01-01 2023-12-31 0001611746 ifrs-full:SharePremiumMember 2022-12-31 0001611746 ifrs-full:ReserveOfSharebasedPaymentsMember 2022-12-31 0001611746 ifrs-full:WarrantsMember 2022-12-31 0001611746 ifrs-full:OtherEquityInterestMember 2022-12-31 0001611746 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2022-12-31 0001611746 ifrs-full:RetainedEarningsMember 2022-12-31 0001611746 ifrs-full:ParentMember 2022-12-31 0001611746 ifrs-full:NoncontrollingInterestsMember 2022-12-31 0001611746 2022-12-31 0001611746 ifrs-full:SharePremiumMember 2023-01-01 2023-12-31 0001611746 ifrs-full:ReserveOfSharebasedPaymentsMember 2023-01-01 2023-12-31 0001611746 ifrs-full:WarrantsMember 2023-01-01 2023-12-31 0001611746 ifrs-full:OtherEquityInterestMember 2023-01-01 2023-12-31 0001611746 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2023-01-01 2023-12-31 0001611746 ifrs-full:RetainedEarningsMember 2023-01-01 2023-12-31 0001611746 ifrs-full:ParentMember 2023-01-01 2023-12-31 0001611746 ifrs-full:NoncontrollingInterestsMember 2023-01-01 2023-12-31 0001611746 ifrs-full:SharePremiumMember 2023-12-31 0001611746 ifrs-full:ReserveOfSharebasedPaymentsMember 2023-12-31 0001611746 ifrs-full:WarrantsMember 2023-12-31 0001611746 ifrs-full:OtherEquityInterestMember 2023-12-31 0001611746 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2023-12-31 0001611746 ifrs-full:RetainedEarningsMember 2023-12-31 0001611746 ifrs-full:ParentMember 2023-12-31 0001611746 ifrs-full:NoncontrollingInterestsMember 2023-12-31 0001611746 2023-12-31 0001611746 ifrs-full:SharePremiumMember 2024-01-01 2024-12-31 0001611746 ifrs-full:ReserveOfSharebasedPaymentsMember 2024-01-01 2024-12-31 0001611746 ifrs-full:WarrantsMember 2024-01-01 2024-12-31 0001611746 ifrs-full:OtherEquityInterestMember 2024-01-01 2024-12-31 0001611746 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2024-01-01 2024-12-31 0001611746 ifrs-full:RetainedEarningsMember 2024-01-01 2024-12-31 0001611746 ifrs-full:ParentMember 2024-01-01 2024-12-31 0001611746 ifrs-full:NoncontrollingInterestsMember 2024-01-01 2024-12-31 0001611746 ifrs-full:SharePremiumMember 2024-12-31 0001611746 ifrs-full:ReserveOfSharebasedPaymentsMember 2024-12-31 0001611746 ifrs-full:WarrantsMember 2024-12-31 0001611746 ifrs-full:OtherEquityInterestMember 2024-12-31 0001611746 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2024-12-31 0001611746 ifrs-full:RetainedEarningsMember 2024-12-31 0001611746 ifrs-full:ParentMember 2024-12-31 0001611746 ifrs-full:NoncontrollingInterestsMember 2024-12-31 0001611746 ifrs-full:SharePremiumMember 2025-01-01 2025-12-31 0001611746 ifrs-full:ReserveOfSharebasedPaymentsMember 2025-01-01 2025-12-31 0001611746 ifrs-full:WarrantsMember 2025-01-01 2025-12-31 0001611746 ifrs-full:OtherEquityInterestMember 2025-01-01 2025-12-31 0001611746 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2025-01-01 2025-12-31 0001611746 ifrs-full:RetainedEarningsMember 2025-01-01 2025-12-31 0001611746 ifrs-full:ParentMember 2025-01-01 2025-12-31 0001611746 ifrs-full:NoncontrollingInterestsMember 2025-01-01 2025-12-31 0001611746 ifrs-full:SharePremiumMember 2025-12-31 0001611746 ifrs-full:ReserveOfSharebasedPaymentsMember 2025-12-31 0001611746 ifrs-full:WarrantsMember 2025-12-31 0001611746 ifrs-full:OtherEquityInterestMember 2025-12-31 0001611746 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2025-12-31 0001611746 ifrs-full:RetainedEarningsMember 2025-12-31 0001611746 ifrs-full:ParentMember 2025-12-31 0001611746 ifrs-full:NoncontrollingInterestsMember 2025-12-31 0001611746 2025-10-22 0001611746 ifrs-full:MajorOrdinaryShareTransactionsMember 2025-01-01 2025-12-31 0001611746 ifrs-full:CommunicationAndNetworkEquipmentMember ifrs-full:BottomOfRangeMember 2025-01-01 2025-12-31 0001611746 ifrs-full:CommunicationAndNetworkEquipmentMember ifrs-full:TopOfRangeMember 2025-01-01 2025-12-31 0001611746 ifrs-full:CommunicationAndNetworkEquipmentMember 2025-01-01 2025-12-31 0001611746 ifrs-full:ComputerEquipmentMember ifrs-full:BottomOfRangeMember 2025-01-01 2025-12-31 0001611746 ifrs-full:ComputerEquipmentMember ifrs-full:TopOfRangeMember 2025-01-01 2025-12-31 0001611746 ifrs-full:ComputerEquipmentMember 2025-01-01 2025-12-31 0001611746 ifrs-full:OfficeEquipmentMember ifrs-full:BottomOfRangeMember 2025-01-01 2025-12-31 0001611746 ifrs-full:OfficeEquipmentMember ifrs-full:TopOfRangeMember 2025-01-01 2025-12-31 0001611746 ifrs-full:OfficeEquipmentMember 2025-01-01 2025-12-31 0001611746 currency:USD 2025-12-31 0001611746 currency:USD 2024-12-31 0001611746 currency:CAD 2025-12-31 0001611746 currency:CAD 2024-12-31 0001611746 currency:ILS 2025-12-31 0001611746 currency:ILS 2024-12-31 0001611746 2022-03-10 2022-03-10 0001611746 sprc:MitoCareXMember 2022-01-01 2022-12-31 0001611746 2023-02-17 0001611746 sprc:MitoCareXMember ifrs-full:BottomOfRangeMember 2023-02-17 2023-02-17 0001611746 sprc:MitoCareXMember ifrs-full:TopOfRangeMember 2023-02-17 2023-02-17 0001611746 sprc:MitoCareXMember 2023-02-17 0001611746 sprc:MitoCareXMember ifrs-full:BottomOfRangeMember 2023-11-25 2023-11-25 0001611746 sprc:MitoCareXMember ifrs-full:TopOfRangeMember 2023-11-25 2023-11-25 0001611746 sprc:MitoCareXMember 2025-03-25 2025-03-25 0001611746 sprc:MitoCareXMember 2024-03-11 2024-03-11 0001611746 sprc:MitoCareXMember 2025-02-25 2025-02-25 0001611746 sprc:MitoCareXMember 2025-02-25 0001611746 2025-02-25 0001611746 sprc:MitoCareXMember 2025-01-01 2025-12-31 0001611746 sprc:MitoCareXMember 2024-01-01 2024-12-31 0001611746 sprc:MitoCareXMember 2023-01-01 2023-12-31 0001611746 2021-12-31 0001611746 sprc:InitialPublicOfferingMember 2022-11-17 2022-11-17 0001611746 sprc:InitialPublicOfferingMember 2022-11-17 0001611746 2022-11-17 2022-11-17 0001611746 ifrs-full:OrdinarySharesMember 2025-12-31 0001611746 ifrs-full:BottomOfRangeMember 2025-01-01 2025-12-31 0001611746 sprc:InitialPublicOfferingMember 2025-12-31 0001611746 2023-06-25 2023-06-25 0001611746 2023-06-25 0001611746 sprc:AutoMaxSharesMember 2023-06-25 0001611746 sprc:AutoMaxSharesMember 2023-06-25 2023-06-25 0001611746 sprc:AutoMaxSharesMember 2025-12-31 0001611746 sprc:AutoMaxSharesMember 2024-12-31 0001611746 sprc:BridgeLoanAgreementMember 2024-01-16 0001611746 sprc:BridgeLoanAgreementMember ifrs-full:BottomOfRangeMember 2024-01-16 0001611746 sprc:BridgeLoanAgreementMember ifrs-full:TopOfRangeMember 2024-01-16 0001611746 2024-06-09 0001611746 sprc:BridgeLoanAgreementMember 2024-06-09 0001611746 2024-09-05 0001611746 2025-02-27 0001611746 2025-02-27 2025-02-27 0001611746 sprc:MergerAgreementMember 2024-04-10 2024-04-10 0001611746 2024-04-10 2024-04-10 0001611746 2025-11-20 2025-11-20 0001611746 2025-11-20 0001611746 2024-04-01 0001611746 sprc:LeaseMember 2024-04-01 0001611746 2024-04-01 2024-04-01 0001611746 sprc:CostMember ifrs-full:ComputerEquipmentMember 2024-12-31 0001611746 sprc:CostMember sprc:OfficeEquipmentsMember 2024-12-31 0001611746 sprc:CostMember sprc:RightOfUseAssesMember 2024-12-31 0001611746 sprc:CostMember 2024-12-31 0001611746 sprc:CostMember ifrs-full:ComputerEquipmentMember 2025-01-01 2025-12-31 0001611746 sprc:CostMember sprc:OfficeEquipmentsMember 2025-01-01 2025-12-31 0001611746 sprc:CostMember sprc:RightOfUseAssesMember 2025-01-01 2025-12-31 0001611746 sprc:CostMember 2025-01-01 2025-12-31 0001611746 sprc:CostMember ifrs-full:ComputerEquipmentMember 2025-12-31 0001611746 sprc:CostMember sprc:OfficeEquipmentsMember 2025-12-31 0001611746 sprc:CostMember sprc:RightOfUseAssesMember 2025-12-31 0001611746 sprc:CostMember 2025-12-31 0001611746 sprc:AccumulatedDepreciationMember ifrs-full:ComputerEquipmentMember 2024-12-31 0001611746 sprc:AccumulatedDepreciationMember sprc:OfficeEquipmentsMember 2024-12-31 0001611746 sprc:AccumulatedDepreciationMember sprc:RightOfUseAssesMember 2024-12-31 0001611746 sprc:AccumulatedDepreciationMember 2024-12-31 0001611746 sprc:AccumulatedDepreciationMember ifrs-full:ComputerEquipmentMember 2025-01-01 2025-12-31 0001611746 sprc:AccumulatedDepreciationMember sprc:OfficeEquipmentsMember 2025-01-01 2025-12-31 0001611746 sprc:AccumulatedDepreciationMember sprc:RightOfUseAssesMember 2025-01-01 2025-12-31 0001611746 sprc:AccumulatedDepreciationMember 2025-01-01 2025-12-31 0001611746 sprc:AccumulatedDepreciationMember ifrs-full:ComputerEquipmentMember 2025-12-31 0001611746 sprc:AccumulatedDepreciationMember sprc:OfficeEquipmentsMember 2025-12-31 0001611746 sprc:AccumulatedDepreciationMember sprc:RightOfUseAssesMember 2025-12-31 0001611746 sprc:AccumulatedDepreciationMember 2025-12-31 0001611746 ifrs-full:ComputerEquipmentMember 2025-12-31 0001611746 sprc:OfficeEquipmentsMember 2025-12-31 0001611746 sprc:RightOfUseAssesMember 2025-12-31 0001611746 sprc:CostMember ifrs-full:ComputerEquipmentMember 2023-12-31 0001611746 sprc:CostMember sprc:OfficeEquipmentsMember 2023-12-31 0001611746 sprc:CostMember sprc:RightOfUseAssesMember 2023-12-31 0001611746 sprc:CostMember 2023-12-31 0001611746 sprc:CostMember ifrs-full:ComputerEquipmentMember 2024-01-01 2024-12-31 0001611746 sprc:CostMember sprc:OfficeEquipmentsMember 2024-01-01 2024-12-31 0001611746 sprc:CostMember sprc:RightOfUseAssesMember 2024-01-01 2024-12-31 0001611746 sprc:CostMember 2024-01-01 2024-12-31 0001611746 sprc:AccumulatedDepreciationMember ifrs-full:ComputerEquipmentMember 2023-12-31 0001611746 sprc:AccumulatedDepreciationMember sprc:OfficeEquipmentsMember 2023-12-31 0001611746 sprc:AccumulatedDepreciationMember sprc:RightOfUseAssesMember 2023-12-31 0001611746 sprc:AccumulatedDepreciationMember 2023-12-31 0001611746 sprc:AccumulatedDepreciationMember ifrs-full:ComputerEquipmentMember 2024-01-01 2024-12-31 0001611746 sprc:AccumulatedDepreciationMember sprc:OfficeEquipmentsMember 2024-01-01 2024-12-31 0001611746 sprc:AccumulatedDepreciationMember sprc:RightOfUseAssesMember 2024-01-01 2024-12-31 0001611746 sprc:AccumulatedDepreciationMember 2024-01-01 2024-12-31 0001611746 ifrs-full:ComputerEquipmentMember 2024-12-31 0001611746 sprc:OfficeEquipmentsMember 2024-12-31 0001611746 sprc:RightOfUseAssesMember 2024-12-31 0001611746 ifrs-full:Level1OfFairValueHierarchyMember 2025-12-31 0001611746 ifrs-full:Level2OfFairValueHierarchyMember 2025-12-31 0001611746 ifrs-full:Level3OfFairValueHierarchyMember 2025-12-31 0001611746 ifrs-full:Level1OfFairValueHierarchyMember 2024-12-31 0001611746 ifrs-full:Level2OfFairValueHierarchyMember 2024-12-31 0001611746 ifrs-full:Level3OfFairValueHierarchyMember 2024-12-31 0001611746 sprc:CarryingAmountOneMember 2025-12-31 0001611746 sprc:ContractualCashFlowMember 2025-12-31 0001611746 sprc:OneYearMember 2025-12-31 0001611746 sprc:TwoFiveYearsMember 2025-12-31 0001611746 sprc:CarryingAmountOneMember 2024-12-31 0001611746 sprc:ContractualCashFlowMember 2024-12-31 0001611746 sprc:OneYearMember 2024-12-31 0001611746 sprc:TwoFiveYearsMember 2024-12-31 0001611746 ifrs-full:Level3OfFairValueHierarchyMember 2025-01-01 2025-12-31 0001611746 ifrs-full:Level1OfFairValueHierarchyMember 2025-01-01 2025-12-31 0001611746 ifrs-full:Level2OfFairValueHierarchyMember 2025-01-01 2025-12-31 0001611746 country:IL 2025-01-01 2025-12-31 0001611746 country:IL 2024-01-01 2024-12-31 0001611746 country:IL 2023-01-01 2023-12-31 0001611746 country:US 2024-01-01 2024-12-31 0001611746 country:US 2023-01-01 2023-12-31 0001611746 country:US 2025-01-01 2025-12-31 0001611746 country:CA 2025-01-01 2025-12-31 0001611746 country:CA 2024-01-01 2024-12-31 0001611746 country:CA 2023-01-01 2023-12-31 0001611746 sprc:SNIsMember 2025-12-31 0001611746 sprc:NeuroTherasMember 2025-12-31 0001611746 2021-12-02 2021-12-02 0001611746 2022-07-27 2022-07-27 0001611746 2023-09-28 0001611746 2025-07-03 0001611746 sprc:SubsequentEventsMember 2026-02-05 0001611746 sprc:NexeraTechnologiesLtdMember 2023-03-22 2023-03-22 0001611746 2023-08-14 2023-08-14 0001611746 sprc:August2023FinancingRoundMember 2023-08-14 2023-08-14 0001611746 sprc:August2023FinancingRoundMember sprc:PrefundedWarrantsMember 2023-08-14 2023-08-14 0001611746 sprc:October2023FinancingRoundMember 2023-10-13 2023-10-13 0001611746 sprc:October2023FinancingRoundMember sprc:PrefundedWarrantsMember 2023-10-13 0001611746 sprc:October2023FinancingRoundMember sprc:PrefundedWarrantsMember 2023-10-13 2023-10-13 0001611746 sprc:PrefundedWarrantsMember 2024-12-31 0001611746 sprc:PrefundedWarrantsMember 2024-01-01 2024-12-31 0001611746 sprc:January2024StandbyEquityPurchaseAgreementMember 2024-01-21 2024-01-21 0001611746 sprc:January2024StandbyEquityPurchaseAgreementMember 2024-01-01 2024-12-31 0001611746 sprc:SEPAMember sprc:January2024StandbyEquityPurchaseAgreementMember 2024-01-01 2024-12-31 0001611746 sprc:January2024StandbyEquityPurchaseAgreementMember 2024-12-31 0001611746 ifrs-full:BottomOfRangeMember sprc:January2024StandbyEquityPurchaseAgreementMember 2024-12-31 0001611746 ifrs-full:TopOfRangeMember sprc:January2024StandbyEquityPurchaseAgreementMember 2024-12-31 0001611746 sprc:ConvertibleDebenturesMember sprc:August2025ConvertibleDebentureExercisesMember 2025-02-25 0001611746 sprc:SecuritiesPurchaseAgreementsMember 2025-08-31 0001611746 sprc:ConvertibleDebenturesMember 2025-01-01 2025-12-31 0001611746 sprc:SecuritiesPurchaseAgreementsMember 2025-12-31 0001611746 sprc:InducementLettersMember 2025-09-26 0001611746 sprc:InducementLettersMember 2025-02-25 0001611746 sprc:InducementLettersMember 2025-02-25 2025-02-25 0001611746 sprc:ExistingWarrantsMember 2025-01-01 2025-12-31 0001611746 sprc:SecuritiesPurchaseAgreementsMember 2025-11-27 0001611746 sprc:SecuritiesPurchaseAgreementsMember 2025-11-27 2025-11-27 0001611746 sprc:MarchTwoThousandAndTwentyOneSeriesAWarrantsMember 2025-01-01 2025-12-31 0001611746 sprc:MarchTwoThousandAndTwentyOneSeriesBWarrantsMember 2025-01-01 2025-12-31 0001611746 sprc:MayTwoThousandAndTwentyTwoWarrantsMember 2025-01-01 2025-12-31 0001611746 ifrs-full:OrdinarySharesMember 2023-12-28 0001611746 ifrs-full:OrdinarySharesMember ifrs-full:ShareOptionsMember 2025-01-01 2025-12-31 0001611746 ifrs-full:OrdinarySharesMember ifrs-full:ShareOptionsMember 2024-01-01 2024-12-31 0001611746 ifrs-full:OrdinarySharesMember ifrs-full:ShareOptionsMember 2023-01-01 2023-12-31 0001611746 ifrs-full:OrdinarySharesMember 2024-12-31 0001611746 ifrs-full:RestrictedShareUnitsMember 2025-01-01 2025-12-31 0001611746 ifrs-full:RestrictedShareUnitsMember 2024-01-01 2024-12-31 0001611746 ifrs-full:ShareOptionsMember 2025-01-01 2025-12-31 0001611746 ifrs-full:ShareOptionsMember 2024-01-01 2024-12-31 0001611746 ifrs-full:ShareOptionsMember 2023-01-01 2023-12-31 0001611746 sprc:PurchasedGoodsMember 2025-01-01 2025-12-31 0001611746 sprc:PurchasedGoodsMember 2024-01-01 2024-12-31 0001611746 sprc:PurchasedGoodsMember 2023-01-01 2023-12-31 0001611746 sprc:FreightMember 2025-01-01 2025-12-31 0001611746 sprc:FreightMember 2024-01-01 2024-12-31 0001611746 sprc:FreightMember 2023-01-01 2023-12-31 0001611746 sprc:WagesAndRelatedExpensesMember 2025-01-01 2025-12-31 0001611746 sprc:WagesAndRelatedExpensesMember 2024-01-01 2024-12-31 0001611746 sprc:WagesAndRelatedExpensesMember 2023-01-01 2023-12-31 0001611746 sprc:ShareBasedPaymentMember 2025-01-01 2025-12-31 0001611746 sprc:ShareBasedPaymentMember 2024-01-01 2024-12-31 0001611746 sprc:ShareBasedPaymentMember 2023-01-01 2023-12-31 0001611746 sprc:RegulatoryProfessionalAndOtherExpensesMember 2025-01-01 2025-12-31 0001611746 sprc:RegulatoryProfessionalAndOtherExpensesMember 2024-01-01 2024-12-31 0001611746 sprc:RegulatoryProfessionalAndOtherExpensesMember 2023-01-01 2023-12-31 0001611746 sprc:ResearchAndPreclinicalStudiesMember 2025-01-01 2025-12-31 0001611746 sprc:ResearchAndPreclinicalStudiesMember 2024-01-01 2024-12-31 0001611746 sprc:ResearchAndPreclinicalStudiesMember 2023-01-01 2023-12-31 0001611746 sprc:ClinicalStudiesMember 2025-01-01 2025-12-31 0001611746 sprc:ClinicalStudiesMember 2024-01-01 2024-12-31 0001611746 sprc:ClinicalStudiesMember 2023-01-01 2023-12-31 0001611746 sprc:ChemistryAndFormulationsMember 2025-01-01 2025-12-31 0001611746 sprc:ChemistryAndFormulationsMember 2024-01-01 2024-12-31 0001611746 sprc:ChemistryAndFormulationsMember 2023-01-01 2023-12-31 0001611746 sprc:AdvertisementMember 2025-01-01 2025-12-31 0001611746 sprc:AdvertisementMember 2024-01-01 2024-12-31 0001611746 sprc:AdvertisementMember 2023-01-01 2023-12-31 0001611746 sprc:AmazonFeesMember 2025-01-01 2025-12-31 0001611746 sprc:AmazonFeesMember 2024-01-01 2024-12-31 0001611746 sprc:AmazonFeesMember 2023-01-01 2023-12-31 0001611746 sprc:AmortizationMember 2025-01-01 2025-12-31 0001611746 sprc:AmortizationMember 2024-01-01 2024-12-31 0001611746 sprc:AmortizationMember 2023-01-01 2023-12-31 0001611746 sprc:StorageAndShippingMember 2025-01-01 2025-12-31 0001611746 sprc:StorageAndShippingMember 2024-01-01 2024-12-31 0001611746 sprc:StorageAndShippingMember 2023-01-01 2023-12-31 0001611746 sprc:ManagementFeesMember 2025-01-01 2025-12-31 0001611746 sprc:ManagementFeesMember 2024-01-01 2024-12-31 0001611746 sprc:ManagementFeesMember 2023-01-01 2023-12-31 0001611746 sprc:ProfessionalAndDirectorsFeesMember 2025-01-01 2025-12-31 0001611746 sprc:ProfessionalAndDirectorsFeesMember 2024-01-01 2024-12-31 0001611746 sprc:ProfessionalAndDirectorsFeesMember 2023-01-01 2023-12-31 0001611746 sprc:DeemedIssuanceListingExpensesMember 2025-01-01 2025-12-31 0001611746 sprc:DeemedIssuanceListingExpensesMember 2024-01-01 2024-12-31 0001611746 sprc:DeemedIssuanceListingExpensesMember 2023-01-01 2023-12-31 0001611746 sprc:BusinessDevelopmentExpensesMember 2025-01-01 2025-12-31 0001611746 sprc:BusinessDevelopmentExpensesMember 2024-01-01 2024-12-31 0001611746 sprc:BusinessDevelopmentExpensesMember 2023-01-01 2023-12-31 0001611746 sprc:RegulatoryExpensesMember 2025-01-01 2025-12-31 0001611746 sprc:RegulatoryExpensesMember 2024-01-01 2024-12-31 0001611746 sprc:RegulatoryExpensesMember 2023-01-01 2023-12-31 0001611746 sprc:OfficeMaintenanceRentAndOtherExpensesMember 2025-01-01 2025-12-31 0001611746 sprc:OfficeMaintenanceRentAndOtherExpensesMember 2024-01-01 2024-12-31 0001611746 sprc:OfficeMaintenanceRentAndOtherExpensesMember 2023-01-01 2023-12-31 0001611746 sprc:InvestorRelationsAndBusinessExpensesMember 2025-01-01 2025-12-31 0001611746 sprc:InvestorRelationsAndBusinessExpensesMember 2024-01-01 2024-12-31 0001611746 sprc:InvestorRelationsAndBusinessExpensesMember 2023-01-01 2023-12-31 0001611746 sprc:LossFromSaleOfPropertyAndEquipmentMember 2025-01-01 2025-12-31 0001611746 sprc:LossFromSaleOfPropertyAndEquipmentMember 2024-01-01 2024-12-31 0001611746 sprc:LossFromSaleOfPropertyAndEquipmentMember 2023-01-01 2023-12-31 0001611746 sprc:GainOnSettlementOfLegalDisputeMember 2025-01-01 2025-12-31 0001611746 sprc:GainOnSettlementOfLegalDisputeMember 2024-01-01 2024-12-31 0001611746 sprc:GainOnSettlementOfLegalDisputeMember 2023-01-01 2023-12-31 0001611746 sprc:OtherIncomeNetMember 2025-01-01 2025-12-31 0001611746 sprc:OtherIncomeNetMember 2024-01-01 2024-12-31 0001611746 sprc:OtherIncomeNetMember 2023-01-01 2023-12-31 0001611746 sprc:GainOnSaleOfPatentLicenseNetnetOfPolyrizonLtdHoldingsSoldMember 2025-01-01 2025-12-31 0001611746 sprc:GainOnSaleOfPatentLicenseNetnetOfPolyrizonLtdHoldingsSoldMember 2024-01-01 2024-12-31 0001611746 sprc:GainOnSaleOfPatentLicenseNetnetOfPolyrizonLtdHoldingsSoldMember 2023-01-01 2023-12-31 0001611746 sprc:NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember 2025-01-01 2025-12-31 0001611746 sprc:NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember 2024-01-01 2024-12-31 0001611746 sprc:NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember 2023-01-01 2023-12-31 0001611746 sprc:FinanceIncomeDueToCancellationOfWarrantLiabilityMember 2025-01-01 2025-12-31 0001611746 sprc:FinanceIncomeDueToCancellationOfWarrantLiabilityMember 2024-01-01 2024-12-31 0001611746 sprc:FinanceIncomeDueToCancellationOfWarrantLiabilityMember 2023-01-01 2023-12-31 0001611746 sprc:FinanceIncomeDueToRevaluationOfConvertibleDebenturesMember 2025-01-01 2025-12-31 0001611746 sprc:FinanceIncomeDueToRevaluationOfConvertibleDebenturesMember 2024-01-01 2024-12-31 0001611746 sprc:FinanceIncomeDueToRevaluationOfConvertibleDebenturesMember 2023-01-01 2023-12-31 0001611746 sprc:InterestFromLoansToRelatedPartiesAndDepositsMember 2025-01-01 2025-12-31 0001611746 sprc:InterestFromLoansToRelatedPartiesAndDepositsMember 2024-01-01 2024-12-31 0001611746 sprc:InterestFromLoansToRelatedPartiesAndDepositsMember 2023-01-01 2023-12-31 0001611746 sprc:ExchangeRateDifferencesNetMember 2025-01-01 2025-12-31 0001611746 sprc:ExchangeRateDifferencesNetMember 2024-01-01 2024-12-31 0001611746 sprc:ExchangeRateDifferencesNetMember 2023-01-01 2023-12-31 0001611746 sprc:ImpairmentOfLoanMember 2025-01-01 2025-12-31 0001611746 sprc:ImpairmentOfLoanMember 2024-01-01 2024-12-31 0001611746 sprc:ImpairmentOfLoanMember 2023-01-01 2023-12-31 0001611746 sprc:IssuanceExpensesRelatedToWarrantsMember 2025-01-01 2025-12-31 0001611746 sprc:IssuanceExpensesRelatedToWarrantsMember 2024-01-01 2024-12-31 0001611746 sprc:IssuanceExpensesRelatedToWarrantsMember 2023-01-01 2023-12-31 0001611746 sprc:LossesFromRemeasurementOfInvestmentInFinancialAssetsMember 2025-01-01 2025-12-31 0001611746 sprc:LossesFromRemeasurementOfInvestmentInFinancialAssetsMember 2024-01-01 2024-12-31 0001611746 sprc:LossesFromRemeasurementOfInvestmentInFinancialAssetsMember 2023-01-01 2023-12-31 0001611746 sprc:FinanceExpenseInRespectOfLeasesMember 2025-01-01 2025-12-31 0001611746 sprc:FinanceExpenseInRespectOfLeasesMember 2024-01-01 2024-12-31 0001611746 sprc:FinanceExpenseInRespectOfLeasesMember 2023-01-01 2023-12-31 0001611746 sprc:FinanceExpensesFromInterestAndCommissionsMember 2025-01-01 2025-12-31 0001611746 sprc:FinanceExpensesFromInterestAndCommissionsMember 2024-01-01 2024-12-31 0001611746 sprc:FinanceExpensesFromInterestAndCommissionsMember 2023-01-01 2023-12-31 0001611746 sprc:OnlineSalesSegmentMember 2024-12-31 0001611746 sprc:DrugDevelopmentMember 2025-01-01 2025-12-31 0001611746 sprc:OnlineSalesMember 2025-01-01 2025-12-31 0001611746 sprc:DrugDevelopmentMember 2024-01-01 2024-12-31 0001611746 sprc:OnlineSalesMember 2024-01-01 2024-12-31 0001611746 sprc:DrugDevelopmentMember 2023-01-01 2023-12-31 0001611746 sprc:OnlineSalesMember 2023-01-01 2023-12-31 0001611746 sprc:DrugDevelopmentMember 2025-12-31 0001611746 sprc:OnlineSalesMember 2025-12-31 0001611746 sprc:DrugDevelopmentMember 2024-12-31 0001611746 sprc:OnlineSalesMember 2024-12-31 0001611746 2023-11-01 2023-11-30 0001611746 sprc:WellutionBrandMember 2024-01-01 2024-12-31 0001611746 sprc:WellutionBrandMember 2025-01-01 2025-12-31 0001611746 sprc:NexeraTechnologiesLtdMember 2023-12-31 0001611746 sprc:NexeraTechnologiesLtdMember 2025-01-01 2025-12-31 0001611746 sprc:ClearmindMember 2025-01-01 2025-12-31 0001611746 2022-11-17 0001611746 2024-08-13 2024-08-13 0001611746 sprc:InitialPublicOfferingMember 2024-10-31 0001611746 ifrs-full:OrdinarySharesMember 2024-10-31 0001611746 2024-10-31 2024-10-31 0001611746 ifrs-full:OrdinarySharesMember 2024-10-31 2024-10-31 0001611746 ifrs-full:OrdinarySharesMember ifrs-full:WarrantsMember 2024-10-31 2024-10-31 0001611746 sprc:PrefundedWarrantsMember 2024-10-31 0001611746 sprc:PrefundedWarrantsMember 2024-10-31 2024-10-31 0001611746 ifrs-full:OrdinarySharesMember sprc:PrefundedWarrantsMember 2024-10-31 2024-10-31 0001611746 ifrs-full:WarrantsMember 2024-10-31 2024-10-31 0001611746 sprc:CommonWarrantsMember 2024-12-30 0001611746 sprc:CommonWarrantsMember 2024-12-30 2024-12-30 0001611746 sprc:PolyrizonMember 2025-04-01 0001611746 2025-04-01 0001611746 ifrs-full:WarrantsMember 2025-01-01 2025-12-31 0001611746 ifrs-full:KeyManagementPersonnelOfEntityOrParentMember 2025-12-31 0001611746 ifrs-full:OtherRelatedPartiesMember 2025-12-31 0001611746 ifrs-full:KeyManagementPersonnelOfEntityOrParentMember 2024-12-31 0001611746 ifrs-full:OtherRelatedPartiesMember 2024-12-31 0001611746 sprc:MizaIIIVenturesIncMember sprc:MizaAgreementMember 2025-10-09 2025-10-09 0001611746 sprc:MizaAgreementMember 2025-12-31 0001611746 sprc:MizaAgreementMember 2025-10-22 0001611746 sprc:MizaAgreementMember 2025-10-22 2025-10-22 0001611746 sprc:MizaCommonSharesMember sprc:MizaAgreementMember 2025-10-22 0001611746 ifrs-full:BottomOfRangeMember sprc:MizaAgreementMember 2025-10-22 0001611746 sprc:MizaCommonSharesMember ifrs-full:WarrantsMember sprc:MizaAgreementMember 2025-10-22 0001611746 ifrs-full:WarrantsMember sprc:MizaAgreementMember 2025-10-22 2025-10-22 0001611746 2025-10-22 2025-10-22 0001611746 ifrs-full:TopOfRangeMember sprc:MizaAgreementMember 2025-10-22 0001611746 ifrs-full:BottomOfRangeMember sprc:MizaAgreementMember 2025-10-22 2025-10-22 0001611746 ifrs-full:TopOfRangeMember sprc:MizaAgreementMember 2025-10-22 2025-10-22 0001611746 sprc:MizaCommonSharesMember 2025-12-31 0001611746 sprc:MizaCommonSharesMember sprc:MizaAgreementMember 2025-12-31 0001611746 sprc:NonConvertibleLoansMember sprc:MizaAgreementMember 2025-12-31 0001611746 sprc:NonConvertibleLoansMember sprc:MizaAgreementMember 2025-01-01 2025-12-31 0001611746 sprc:UnsecuredConvertibleLoansMember sprc:MizaAgreementMember 2025-10-23 0001611746 sprc:MizaCommonSharesMember sprc:MizaAgreementMember 2025-10-23 0001611746 sprc:SubsequentEventsMember 2026-01-26 0001611746 sprc:SubsequentEventsMember 2026-01-13 0001611746 sprc:SubsequentEventsMember 2026-01-13 2026-01-13 0001611746 sprc:SubsequentEventsMember 2026-02-12 0001611746 sprc:ForecastMember 2026-04-01 0001611746 2026-04-01 2026-04-01 0001611746 sprc:InitialWarrantMember sprc:ForecastMember 2026-04-01 0001611746 sprc:InitialWarrantMember sprc:ForecastMember 2026-04-01 2026-04-01 0001611746 sprc:SubsequentEventsMember sprc:NeuroTheraMember 2026-03-10 2026-03-10 0001611746 sprc:SubsequentEventsMember sprc:CliniQuantumLtdMember 2026-03-10 0001611746 ifrs-full:OrdinarySharesMember sprc:SubsequentEventsMember sprc:CliniQuantumLtdMember 2026-03-10 0001611746 sprc:SubsequentEventsMember sprc:NeuroTheraMember 2026-03-10 0001611746 sprc:SubsequentEventsMember 2026-03-10 2026-03-10 0001611746 sprc:SubsequentEventsMember 2026-03-10 0001611746 sprc:SubsequentEventsMember ifrs-full:BottomOfRangeMember 2026-03-10 0001611746 sprc:SubsequentEventsMember ifrs-full:TopOfRangeMember 2026-03-10 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure iso4217:ILS iso4217:ILS xbrli:shares utr:sqm iso4217:CAD xbrli:shares iso4217:CAD

ATTACHMENTS / EXHIBITS

ATTACHMENTS / EXHIBITS

CERTIFICATION

CERTIFICATION

CONSENT OF KOST FORER GABBAY & KASIERER, A MEMBER OF EY GLOBAL, INDEPENDENT REGISTERED ACCOUNTING FIRM FOR THE REGISTRANT

CONSENT OF BRIGHTMAN ALMAGOR ZOHAR & CO., A FIRM IN THE DELOITTE GLOBAL NETWORK

XBRL SCHEMA FILE

XBRL CALCULATION FILE

XBRL DEFINITION FILE

XBRL LABEL FILE

XBRL PRESENTATION FILE

IDEA: R1.htm

IDEA: ea0302520-20fa1_scisparc_htm.xml

IDEA: R2.htm

IDEA: R3.htm

IDEA: R4.htm

IDEA: R5.htm

IDEA: R6.htm

IDEA: R7.htm

IDEA: R8.htm

IDEA: R9.htm

IDEA: R10.htm

IDEA: R11.htm

IDEA: R12.htm

IDEA: R13.htm

IDEA: R14.htm

IDEA: R15.htm

IDEA: R16.htm

IDEA: R17.htm

IDEA: R18.htm

IDEA: R19.htm

IDEA: R20.htm

IDEA: R21.htm

IDEA: R22.htm

IDEA: R23.htm

IDEA: R24.htm

IDEA: R25.htm

IDEA: R26.htm

IDEA: R27.htm

IDEA: R28.htm

IDEA: R29.htm

IDEA: R30.htm

IDEA: R31.htm

IDEA: R32.htm

IDEA: R33.htm

IDEA: R34.htm

IDEA: R35.htm

IDEA: R36.htm

IDEA: R37.htm

IDEA: R38.htm

IDEA: R39.htm

IDEA: R40.htm

IDEA: R41.htm

IDEA: R42.htm

IDEA: R43.htm

IDEA: R44.htm

IDEA: R45.htm

IDEA: R46.htm

IDEA: R47.htm

IDEA: R48.htm

IDEA: R49.htm

IDEA: R50.htm

IDEA: R51.htm

IDEA: R52.htm

IDEA: R53.htm

IDEA: R54.htm

IDEA: R55.htm

IDEA: R56.htm

IDEA: R57.htm

IDEA: R58.htm

IDEA: R59.htm

IDEA: R60.htm

IDEA: R61.htm

IDEA: R62.htm

IDEA: R63.htm

IDEA: R64.htm

IDEA: R65.htm

IDEA: R66.htm

IDEA: R67.htm

IDEA: R68.htm

IDEA: R69.htm

IDEA: R70.htm

IDEA: R71.htm

IDEA: R72.htm

IDEA: R73.htm

IDEA: R74.htm

IDEA: R75.htm

IDEA: R76.htm

IDEA: R77.htm

IDEA: R78.htm

IDEA: R79.htm

IDEA: R80.htm

IDEA: R81.htm

IDEA: R82.htm

IDEA: R83.htm

IDEA: R84.htm

IDEA: R85.htm

IDEA: R86.htm

IDEA: R87.htm

IDEA: R88.htm

IDEA: R89.htm

IDEA: R90.htm

IDEA: R91.htm

IDEA: R92.htm

IDEA: R93.htm

IDEA: R94.htm

IDEA: FilingSummary.xml

IDEA: MetaLinks.json